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Summary 
Antibodies and antibody fragments are essential tools in basic research, diagnostics and 
therapy. Conventional antibodies consist of two heavy and two light chains with both chains 
contributing to the antigen-binding site. In addition to these conventional antibodies, 
camelids (llamas, alpacas, dromedaries and camels) possess so-called heavy chain antibodies 
(hcAbs) that lack the light chains. The antigen binding site of these unusual antibodies is 
formed by one single domain only, the so called VHH domain. The VHH domain represents 
the smallest intact antigen binding fragment (~ 15 kDa) and is characterized by very high 
stability, solubility and specificity. These unique features render VHHs a promising alternative 
to conventional antibodies and antibody fragments with a multitude of possible applications. 
In the course of this thesis, we aimed to generate and characterize VHHs suitable for 
different applications ranging from biochemical studies to immunofluorescence assays and 
live cell imaging. In order to meet the diverse requirements of the intended downstream 
applications, a new selection method differing from traditional phage display, called native 
panning, was developed and established. In combination with the protein-protein 
interaction fluorescent two-hybrid (F2H) assay, a new process to identify antigen specific 
VHHs functional inside living cells was developed. 
We used the immune system of alpacas to generate VHH libraries against various 
antigens, ranging from small peptides to large proteins. The libraries were screened by 
phage display and antigen specific VHHs were identified by phage ELISA. We were able to 
identify antigen specific VHHs against different antigens which were characterized and their 
functionality was tested in various applications. Furthermore, we could demonstrate that 
the selection method influences which VHHs are identified and therefore needs to be chosen 
very carefully with regard to the intended biochemical and cell biological application. In 
summary, we developed and established an efficient and versatile process to screen and 
identify antigen specific VHHs suitable for different downstream applications.
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Zusammenfassung 
Antikörper und rekombinante Antikörperfragmente sind unabkömmliche Werkzeuge in 
der biomedizinischen Forschung, Diagnostik und Therapie. Klassische Antikörper sind durch 
einen sehr komplexen Aufbau mit zwei schweren und zwei leichten Ketten gekennzeichnet. 
Neben den klassischen Antikörpern besitzen Cameliden (Lamas, Alpakas, Dromedare und 
Kamele) zusätzlich so genannte Schwere-Ketten-Antikörper, welchen die leichten Ketten 
fehlen. Dadurch wird die Antigenbindung lediglich durch eine einzelne Domäne, die VHH 
(variable heavy chain of heavy chain antibodies)-Domäne, vermittelt. Die VHH-Domäne ist 
das kleinste bisher bekannte, natürlich vorkommende antigenbindende Fragment (~ 15 kDa) 
und zeichnet sich durch eine hohe Affinität und Spezifität zu ihrem Antigen aus. Aufgrund 
ihrer geringen Größe und Komplexität können VHHs schnell und einfach als rekombinantes 
Protein in bakteriellen Expressionssystemen hergestellt werden. Darüber hinaus besitzen sie 
eine hohe Stabilität und Löslichkeit. Durch diese Eigenschaften stellen VHHs eine 
vielversprechende Alternative zu klassischen Antikörpern und Antikörperfragmenten dar. 
Schwerpunkt dieser Arbeit war es neue VHHs zu identifizieren und zu charakterisieren, 
die für verschiedenste biochemische und zellbiologische Anwendungen geeignet sind. Um 
den vielfältigen Anforderungen in Anwendungen gerecht zu werden, wurde ein neues 
Selektionsverfahren entwickelt und etabliert, das so genannte native panning. In 
Kombination mit dem Protein-Protein-Interaktions fluorescent two-hybrid (F2H) assay wurde 
ein neuer Prozess zur Identifikation von antigenspezifischen VHHs entwickelt. 
Im Rahmen dieser Arbeit wurden antigenspezifische VHHs gegen verschiedene Antigene 
identifiziert und charakterisiert. Darüber hinaus wurde deren Eignung und Funktionalität in 
verschiedenen biochemischen und zellbiologischen Anwendungen getestet. 
Zusammenfassend wurde ein effizienter und flexibler Prozeß zur Selektion und Identifikation 
von antigenspezifischen VHHs für die Verwendung in einer Vielzahl von Anwendungen 
entwickelt und etabliert. 
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1 Introduction 
The term „Antibody“ was first used in the last decade of the 19th century. In October 
1890, Emil von Behring and Shibasaburo Kitasato mentioned the term “Antikörper” in their 
study “Ueber das Zustandekommen der Diphterie-Immunität und der Tetanus-Immunität bei 
Thieren”(Behring and Kitasato, 1890). In their conclusion they suggested that antibodies are 
able to specifically eliminate diphtheria and tetanus toxins and thus completely prevent the 
symptoms of the diseases. In 1901 Behring was awarded The Nobel Prize in Physiology or 
Medicine for his findings.  
Today, more than one hundred years after the first mention of antibodies, these 
molecules are one of the best studied and characterized proteins. This is not only due to 
their key function in the defense mechanism of higher vertebrates, but also due to their 
extensive use in biomedical research, diagnostics and therapy with many approaches being 
unimaginable without employment of antibodies. However, the remarkable success of 
antibodies has not yet reached its peak and new applications and approaches using 
antibodies are developed still. 
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1.1 Antibodies 
Upon an infection of a mammalian organism, two major systems try to counteract the 
pathogen invasion in the body. Initially, the innate immune system provides an immediate, 
non-specific response after the invasion of an unknown pathogen (Medzhitov, 2007) 
(Beutler, 2004). If the infection continues, the response of the adaptive immune system is 
initiated. The adaptive immune response is antigen-dependent and specific and is developed 
during the lifetime of an individual. It is based on a highly sophisticated interplay between a 
variety of different cell types and molecules among which lymphocytes and antibodies are 
the key elements. There are two types of lymphocytes, T cells and B cells. T cells are 
responsible for cellular immune response, while B cells are essential for the humoral 
immune response. In both cases the immune response is stimulated by specific antigens 
which can range from small chemical structures, through sugars, lipids, peptides and 
nucleotides to highly complex molecules, such as proteins or protein complexes (Delves and 
Roitt, 2000) (Collis et al., 2003). 
During humoral immune response, B cells are providing both specific and long-lasting 
protection against a diverse range of pathogens (Harwood and Batista, 2010). Once an 
antigen is bound to the surface of a B cell via a B cell receptor (BCR), it gets internalized and 
processed into peptides (Parker, 1993). The processed antigen is returned to the B cell 
surface and presented via the Major Histocompatibility Complex (MHC) II for antigen specific 
helper T cell (TH cell) recognition (Noelle and Snow, 1992). The physical contact between B 
and TH cell triggers the production of specific interleukins including IL-4, IL-5 and IL-6 which 
in turn activate B cells (Parker, 1993). IL-4 activates clonal proliferation, while IL-5 and IL-6 
induce the differentiation of the B cell. The activated B cells either differentiate into memory 
B cells providing long-term protection against secondary infection or into antibody secreting 
plasma cells (Reth, 1992). 
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In the immune system antibodies are responsible for recognition and binding of foreign 
structures. They protect the host in different ways. First, they neutralize toxic effects of 
pathogens by binding pathogens and hence preventing infection. Second, they facilitate 
uptake of the pathogen by phagocytosis and third, they recruit natural killer (NK) cells by 
binding to the surface of a pathogen enabling NK cells to destroy the antibody-coated cells in 
a process called antibody-dependent cell-mediated cytotoxicity (ADCC). 
1.1.1 Structure and Function of Antibodies 
Antibodies are capable of specifically recognizing an enormous variety of different 
antigens, however, they do not recognize whole antigens, but parts of it referred to as 
epitopes. The diversity of antibodies is based on their modular architecture making it 
possible to generate up to 1015 different antibodies. The basic antibody molecule (~150 kDa) 
also referred to as immunoglobulin (Ig), consists of two identical heavy (H) chains and two 
identical light (L) chains, while two types of light chains (κ and λ) and five types of heavy 
chains (µ, δ, γ, ε and α) can be discriminated. Heavy and light chains are linked covalently by 
disulfide bonds (Porter, 1963). Both, the heavy (~ 50 kDa) and light chain (~25 kDa) are 
composed of two regions with distinct variability of their amino acid sequence (Johnson and 
Wu, 2000) (Hilschmann and Craig, 1965): the variable (V) region at the N-terminus and the 
constant (C) region at the C-terminus (Cohen and Milstein, 1967). Each light chain consists of 
one variable domain (VL) and one constant domain (CL). Each heavy chain, however, consists 
of one variable domain (VH) and up to four constant domains (CH). The so called hinge region 
is located between variable and constant regions of the heavy chain forming the typical Y-
shaped structure of an antibody. 
Antibody molecules can be cleaved in distinct fragments after incubation with the 
protease papain. It cuts the molecule in the hinge region to yield the Fab (fragment antigen 
binding; ~45 kDa) and the Fc (fragment crystallizable; ~50 kDa) part of the molecule (see 
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Figure 1). The Fab part retains the antigen binding activity while the Fc part contains most of 
the constant region of the heavy chains (Delves and Roitt, 2000). 
 
Figure 1: General structure of an immunoglobulin in higher vertebrates. It consists of two identical heavy 
(each consisting of VH, CH1, CH2, CH3) and two identical light chains (each consisting of VL and CL). Heavy and 
light chains are covalently linked by disulfide bonds. Figure modified from (Rothbauer et al., 2006). 
Five classes of immunoglobulins can be discriminated, IgM, IgD, IgG, IgE and IgA which 
are defined by their heavy chain (CH) classes also known as isotypes and designated by the 
lower Greek letters µ, δ, γ, ε and α. After activation of a B cell, IgMs are the first type of 
immunoglobulins which are secreted (Harriman et al., 1993). IgMs comprise the heavy chain 
µ and form a soluble pentamer for effective antigen binding. During a somatic 
recombination process called class switch recombination (CSR) (Li et al., 2004), the gene 
coding for CH is changed from Cµ to Cδ, Cγ, Cε or Cα, allowing for switch of isotype from IgM 
to either IgD, IgG, IgE or IgA, respectively. 
These differences in the heavy chain composition are responsible for distinct 
characteristics and effector functions of each isotype. As described above, IgMs are the first 
antibodies to be produced and hence are responsible for activation of phagocytosis. IgA class 
antibodies are mainly found in mucosal surfaces. IgEs are involved in defense against 
parasites and play a major role in common allergic diseases whereas IgD isotypes exist only 
in minor amounts as antibody in serum and its function is still unsolved (Reth, 1992). During 
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immune response of higher vertebrates IgGs are with 70-75% of the total immunoglobulins 
the most abundant antibodies (Cohen and Milstein, 1967). 
The five isotypes also show structural differences including the number and location of 
disulfide bonds, the number of C domains and the length of the hinge region (see Figure 2). 
The hinge region connects the CH1 and CH2 domain and is responsible for the flexibility of an 
antibody molecule (Padlan, 1994). Since the length of the hinge region varies in the different 
isotypes, the distance between the antigen binding sites differs. While IgD, IgG and IgA class 
antibodies have a hinge region, IgM and IgE class antibodies are lacking a hinge region. 
However, the latter contain an extra C domain thus the CH2 domain could be viewed as 
replacement for the hinge region. 
 
Figure 2: The immunoglobulin isotypes are encoded by a cluster of immunoglobulin heavy chain 
constant region genes. Each immunoglobulin consists of two identical heavy (VH and CH domains) and two 
identical light chains (VL and CL domain). The C region heavy chains are encoded by separate gene segments. 
The constant region for each isotype is indicated by the same color as the C region gene segment that encodes 
it. IgM and IgE lack a hinge, but each contains an extra heavy chain domain. Heavy and light chains are 
covalently linked by disulfide bonds (grey lines) in different number and location. One of the ε genes is a 
pseudogene (ψ). Figure modified from Murphy, 2012 (Murphy et al., 2012). 
1 Introduction 
 
14 
 
In humans, IgGs can be further divided into four subclasses: IgG1, IgG2, IgG3 and IgG4. 
The IgG subclasses are named in order of abundance in serum: IgG1 70 %, IgG2 20 %, IgG3    
7 % and IgG4 3 % (Ochs and Wedgwood, 1987). The structural differences among IgG 
subclasses lie in the length of the hinge region and in the distribution of the disulfide bonds 
(Ochs and Wedgwood, 1987). 
IgGs specifically recognize and bind antigens through the variable region located at the 
N-terminus of the molecule. The variable region differs extensively between antibody 
molecules, but the sequence variability is not, however, distributed equally throughout the 
variable regions but concentrated in three so called hypervariable regions. When VH and VL 
domains are paired in the antibody molecule, three hypervariable loops from each domain 
are brought together creating a single hypervariable site: the antigen-binding site. The 
hypervariable loops form the complementarity determining regions (CDRs) – CDR1, CDR2 
and CDR3. The CDRs are flanked by less variable and highly conserved regions which are 
called framework regions (FR) (Kabat, 1991). However, mutations in FRs are also known to 
influence binding since they play an important role in structure preservation, folding yield 
and stability of the antibody (David et al., 2007) (Padlan, 1994). The CDRs of the light chain 
are roughly six to ten amino acid residues in length, those of the heavy chain are roughly five 
to fifteen amino acid residues in length (see Figure 3) (Kabat, 1991) (Johnson and Wu, 2000) 
(Johnson and Wu, 2000), but they show wide variations in length between species (Collis et 
al., 2003) (Padlan et al., 1995), especially in the CDR3 of heavy chains (Kabat, 1991) which 
often plays a central role in antigen binding (Padlan, 1994). 
 
Figure 3: Schematic illustration of a VH fragment. The three complementarity determining regions (CDRs) 
are flanked by four framework regions (FR). The numbering refers to the position of the amino acid along the 
sequence according to the Kabat numbering (Kabat, 1991). 
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Since antigen-binding is mediated through CDRs from both VH and VL domains, it is the 
combination of heavy and light chain which determines the antigen specificity. As a result, 
antibodies naturally are bivalent with two antigen-binding arms of identical specificity 
(Delves and Roitt, 2000). Antibody-antigen interactions are non-covalent bonds such as 
hydrogen bonds, salt bridges and van der Waals bonds (van Oss et al., 1986) and the 
strength of binding is called affinity. The presence of two identical antigen-binding sites 
allows antibodies to bind simultaneously to two identical antigens and hence increases the 
total strength of the interaction. This cooperative mode of interaction is termed avidity.  
1.1.2 Areas of Application 
The extraordinary binding specificities of antibodies make them arguably most valuable 
tools in biomedical research, diagnostics and therapy. A major breakthrough was the 
development of the hybridoma technology by Georges Köhler and César Milstein in 1975. 
Before, polyclonal antibodies were used which recognize many epitopes of the same antigen 
and which are prone to batch-to-batch variability. By fusion of antibody-producing B cells 
from an immunized mouse with a myeloma cell line Köhler and Milstein were able to 
generate an immortal hybridoma cell, capable to generate limitless amounts of antibodies 
with single antigen specificity, called monoclonal antibodies (mAbs) (Kohler and Milstein, 
1975).  
In basic research, antibodies are key components in many technologies ranging from 
proteomics to cell-based assays. The most prominent examples are the Immuno (Western) 
blot, Immunoprecipitation, Immunofluorescence and Immunhistochemistry. The latter is the 
“gold standard” in the diagnosis of abnormal cells such as those found in tumors. In many 
applications in in vitro diagnosis antibodies also play a major role with antibody-based 
immunoassays being the most commonly used type of diagnostic assay (Borrebaeck, 2000). 
Due to their high specificities antibodies are used in numerous diagnostic tests to detect 
even very small amounts of drugs or hormones, e.g. monoclonal antibodies to human 
1 Introduction 
 
16 
 
chorionic gonadotropin (HCG) are used in pregnancy test kits (Porter et al., 1988). The 
unique features of antibodies allow the development of sensitive and accurate assays to 
quantify and detect markers correlating with specific diseases. Especially the invention of the 
“sandwich immunoassay” which relies on two antibodies recognizing different epitopes in 
the same antigen increased the specificity of those assays (Maiolini and Masseyeff, 1975). In 
addition, antibodies are important clinical reagents used in diagnostic imaging when 
radiolabelled antibodies are injected into the patient e.g. to bind and to visualize specific 
antigens located on the surface of certain tumor cells (Holliger and Hudson, 2005).  
With more than 20 approved mAbs and more than 200 mAb candidates in the clinical 
pipeline monoclonal antibodies have become established molecules for therapeutic 
applications (Nelson and Reichert, 2009). The efficiency of mAbs in cancer therapy lies in 
their capacity to discriminate tumor-associated antigens at low levels (Holliger and Hudson, 
2005). Due to their bimodal mode of action with specific antigen binding on the one hand 
and effector function activation on the other hand, exogenously administered mAbs function 
like endogenous antibodies and recruit the body´s intrinsic effector mechanisms to fight 
cancer cells or inflammatory diseases. In addition, they can also be armed with anticancer 
drugs, radioisotopes or toxins (Boyiadzis and Foon, 2008).  
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1.2 Display Technologies and Recombinant Antibody Formats  
Antibodies are an important and growing class of research reagents and 
biopharmaceutical products. Despite being widely applied, conventional antibodies have 
several disadvantages. Naturally, immunoglobulins are secreted from plasma cells or are 
anchored at the cell surface as an essential part of the defense strategy against pathogens; 
however, their application in cell based assays within the cytoplasm of live cells is limited. 
The reducing environment of the cytoplasm prevents the oxidative formation of both inter- 
and intramolecular disulfide bonds which are essential for functional antibody folding 
(Cattaneo and Biocca, 1999) (Biocca et al., 1990). Thus, the general application of antibodies 
in cell based assays is restricted to endpoint assays in dead cells or tissues due to necessary 
fixation and permeabilization techniques. 
For diagnostic in vivo imaging, the use of antibody molecules can be limited due to their 
isotype, since the constant Fc parts have the tendency to nonspecifically bind and visualize 
not only the target of interest but also other structures in the body (Harwood et al., 1985). 
Due to their complex composition and posttranslational modifications antibodies need to be 
manufactured in costly eukaryotic expression systems like mouse hybridoma cells 
(Steinmeyer and McCormick, 2008). 
Furthermore, although in basic research monoclonal antibodies are very common and 
easily handled, the use of antibodies derived from nonhuman sources like mouse in human 
therapy, however, is hindered by the patients´ immune response eliciting human anti-mouse 
antibodies (HAMA) (Carter, 2001). One approach to avoid this immune response is 
humanization of antibodies. This can be achieved either by recombinant grafting of the 
entire variable domains onto human constant regions (Morrison et al., 1988) or through 
generation of transgenic mice producing human immunoglobulins (Jakobovits, 1995). The 
most prominent humanized mAbs used in therapeutics are Rituximab (trade name Rituxan®) 
and Trastuzumab (trade name Herceptin®). Rituximab is used to treat rheumatoid arthritis 
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and Non-Hodgkins-Lymphoma (Feldmann, 2002), Trastuzumab is used to treat breast cancer 
by targeting the human EGFR 2 receptor which is overexpressed on 20-30 % breast cancers 
(Boyiadzis and Foon, 2008). 
Generation of monoclonal antibodies requires immune response following 
immunization. Thus, antibodies against non-immunogenic substances, such as non-protein 
components, toxic substances or highly conserved antigens are not easily obtained. In 
continuous search for improving and extending antibody applications, alternative 
recombinant antibody formats have been developed. 
1.2.1 Recombinant Antibody Formats 
Recombinant antibodies are produced by genetic engineering as opposed to naturally 
occurring in the body. Genetic engineering is used to create antibody libraries based on 
antibody gene segments that are diversified by mutagenesis. Since recombinant antibodies 
are generated outside an organism, it is possible to obtain antibodies which usually are not 
being elicited by the immune system, e.g. due to transient conformational change of an 
antigen after cofactor binding (Nizak et al., 2003). Among different recombinant antibody 
fragments scFvs (single-chain variable Fragment) and Fabs (fragment antigen binding) are 
the most prominent (Knappik and Brundiers) (see Figure 4). 
 
Figure 4: Schematic illustration of different antibody formats derived from conventional antibodies. In 
dark shading the heavy chain, the light chain in lighter shading. Modified after Zolghadr et al, 2007. 
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1.2.1.1 ScFv fragments 
The smallest antigen-binding fragment is the single Fv fragment, namely VH or VL domain. 
However, VHs have a rather hydrophobic interface which stabilizes the heterodimer with the 
VL (Chothia et al., 1985). Thus, single VH domains tend to aggregate since they have an 
exposed hydrophobic surface due to the missing VL interaction (Ward et al., 1989). VL 
domains on the other hand may dimerize with themselves and by this block the essential 
antigen binding site (Pluckthun, 1992). 
The next smaller, but much more stable binding unit is the scFv fragment (~25 kDa) 
hence representing the minimal recombinant antigen-binding fragment of antibodies 
(Hudson, 1998). It consists of the two variable domains, VH and VL. Naturally, VH and VL 
domain are non-covalently associated via a hydrophobic interaction and tend to dissociate 
(Winter and Milstein, 1991). However, stable Fv fragments can be engineered by linking the 
two domains with a hydrophilic and flexible linker ((Gly4Ser)3) to create a single-chain Fv 
(scFv) fragment (Huston et al., 1988). As scFvs are relatively small, unglycosylated proteins 
they can be produced in heterologous expression systems like bacteria or lower eukaryotes 
(Skerra and Pluckthun, 1988). For in vivo imaging scFvs provide fast and efficient tissue 
penetration and show only low non-specific background compared to intact antibodies. In 
addition, the small size of the fragments has been suggested to permit binding to cryptic 
epitopes not accessible to full-sized mAbs (Ward et al., 1989). However, scFvs demonstrate 
short circulating half-lives in the organism due to fast absorbance and excretion by the 
kidney (Sanz et al., 2005). Furthermore, therapeutic applications or diagnostic applications 
are still hampered by stability problems since scFvs still have a strong tendency to aggregate 
due to hydrophobic interactions in a hydrophilic environment (Cattaneo and Biocca, 1999). 
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1.2.1.2 Fab fragments 
Beside scFvs, Fab (~50 kDa) or F(ab)2 (~100 kDa) fragments are the second commonly 
used recombinant antibody fragments. Fabs are generated by proteolytic digestion of full 
length antibodies and comprise the VH and CH1 domains of the immunoglobulin heavy chain 
and the VL and CL domains of the light chain linked together by a disulfide bond. Fab 
fragments are used for diagnostic imaging (Behr et al., 1995) and recently were successfully 
tested for in vivo imaging (Elsasser-Beile et al., 2009). Fabs can also be expressed in 
heterologous systems, but at lower expression levels than scFvs (Hudson, 1998).  
1.2.2 Display Technologies 
As described above, recombinant antibodies are derived from antibody libraries. The 
most prominent Fab library is the HuCal library (Knappik et al., 2000) which is a synthetically 
generated library with randomized CDR-regions. To select desired antibodies from such 
libraries, display technologies such as bacterial display, ribosome display and phage display 
have proven to be powerful tools for obtaining antibodies. With these methods, 
recombinant binding molecules can be selected in vitro from comprehensive libraries 
derived synthetically (Knappik et al., 2000) or from immunized (He et al., 1999) or naïve 
animals (de Haard et al., 1999). 
The basic principle of all display technologies is to physically link the phenotype (binding 
entity) to the genotype (genetic information) (He and Khan, 2005). While bacterial display 
enables the display of antibody fragments on surfaces of cells, ribosome display is a cell-free 
display technique which takes place completely in vitro. By generating antibody-ribosome-
mRNA complexes individual antibody fragments are linked to their corresponding mRNA and 
selected through affinity capture via a ligand (Mattheakis et al., 1994; Hanes and Plückthun, 
1997). 
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1.2.2.1 Phage Display 
The most widely used in vitro technology is the phage display technology which takes 
advantage of the coat protein of filamentous bacteriophages (Smith, 1985). The most 
commonly used bacteriophage in phage display is the filamentous M13 phage (see Figure 5), 
which can infect E. coli without killing or lysing the bacteria. These bacteriophages are 
characterized by a filamentary structure with a length of ~ 1-2 µm and a diameter of ~ 7 nm. 
The phage genome of 6400 kb encodes for 11 proteins: five capsid proteins (pIII, pVI, pVII, 
pVIII, pIX), three assembly proteins (pI, pIV, pXI) and three replications proteins (pII, pV, pX). 
The capsid comprises five different proteins while pVIII being the most abundant with ~2700 
copies. The tips of the phages contain five copies of pIII and pVI each on one side and five 
copies of pVII and pIX each on the other side. 
 
Figure 5: Schematic illustration of M13 phage. Modified from Jegg, 2007. 
Phage display enables selection of peptides, proteins or antibodies with desired binding 
properties from a large collection of variants, a so called phage display library. Such libraries 
are generated by genetic fusion of genes of interest to those of phage coat proteins (pIII or 
pVIII) using a special phagemid vector which is then transformed in E. coli. Phagemids 
contain both an E. coli and a phage specific replication origin and a selection marker 
(resistance) (Arbabi Ghahroudi et al., 1997). However, phagemids lack genes responsible for 
packaging, replication and other coat proteins making them dependent on helper phages 
which are coinfected with the phagemids into host bacteria encoding the proteins necessary 
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to generate complete phage particles (Sidhu, 2001), hence resulting in release of phage 
particles expressing the encoded protein on their tip (display). In case of antibody phage 
display, antibodies or antibody fragments are presented.  
After infection of phagemid transformed E. coli with the bacteriophage, phage particles 
with the antibody fragment on their tips are released. The appropriate antibody is selected 
by exposing the phage library to an immobilized antigen, a technique known as panning 
(McCafferty et al., 1990). During this process, phages that display an antibody fragment 
which binds to the immobilized antigen will be retained while non-adherent phages will be 
washed away. Bound phages can be recovered from the surface, reinfected into bacteria and 
regrown for the next round of enrichment (Willats, 2002) (see Figure 6). 
Even being the most widely used selection method for antibody fragments, panning with 
immobilized antigen may have serious drawbacks regarding the selection of antibody 
fragments specific for natively folded antigens. Although the immobilization of antigens on 
plastic surfaces is usually very efficient, it may be problematic since the passive adsorption 
on plastic is a mechanism of protein denaturation. It has been shown that protein molecules 
when absorbed on to polystyrene undergo conformational changes (Davies et al., 1994). 
Hence, antigens may become partially denatured, leading to the selection of antibody 
fragments which recognize epitopes, only present in denatured molecules (Chames et al., 
2001). 
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Figure 6: Panning. A phage library with phages presenting antibody variants at their tips is exposed to 
immobilized antigens (1.). Non-binding phages are washed off, however, some non-specific binding may occur 
(2.). Bound phages are eluted (3.). Eluted phages are used for infection of E. coli (4.). By amplification of the 
bacteria a further library is generated (5.) and used for the next phage display cycle (6.). Figure modified from 
Willats et al., 2002. 
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1.3 Heavy chain antibodies 
In search of smaller antigen binding fragments still capable of recognizing antigens with 
high specificity and affinity, Hamers-Casterman and colleagues made a remarkable discovery 
in 1993. They found a structurally different kind of antibodies which are part of the humoral 
immune response in the serum of camelids (camels, dromedaries, lamas, alpacas) (Hamers-
Casterman et al., 1993). In addition to conventional IgG antibodies (as described in 1.1), 
which are well conserved among mammals, camelids contain so called heavy chain 
antibodies (hcAbs). Accordingly, these antibodies are composed of heavy chains only and are 
devoid of light chains. HcAbs are absent in other mammals except in pathological cases 
where parts of the V domain and/or CH1 exon have been removed (Alexander et al., 1982). 
Nevertheless, in 1995 Greenberg and colleagues found similar hcAbs in nurse sharks 
(Greenberg et al., 1995), but evolutionary analysis showed that camelid and shark hcAbs 
evolved independently (Nguyen et al., 2002). There are many speculations about the driving 
force for the emergence of heavy chain antibodies in such distantly related species, 
however, the rationale for the presence of hcAbs is plausible: in addition to the big 
conventional antibodies, small, single domain antigen binding fragments provide access to 
inaccessible epitopes like catalytic centers of enzymes (Flajnik et al., 2011).  
1.3.1 Structure of Camelidae heavy chain antibodies 
HcAbs of camelids derive from classical IgG antibodies and account for 50 % of the 
circulating immunoglobulins in dromedary (Muyldermans, 2001). The overall structure of the 
hcAbs resembles that of the classical immunoglobulins with a number of important 
deviations (see Figure 7). First, the heavy chain of hcAbs is composed of three instead of four 
domains, the V domain being joined directly to the hinge region and the Fc (Hamers-
Casterman et al., 1993). While the two constant domains at the C terminus (CH2 and CH3) are 
highly homologous to the Fc domains of classical antibodies, the CH1 domain is missing in 
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hcAbs. Second, as mentioned above, the light chains are completely absent in hcAbs. Hence, 
the Fab is reduced to a single variable domain, the so called VHH (variable domain of heavy 
chain antibodies) domain or Nanobody. Antigen binding occurs through this single domain 
only, representing the smallest intact antigen binding fragment (~ 15 kDa) derived from a 
functional immunoglobulin. 
 
Figure 7: Schematic illustration of a conventional IgG and a Camelidae heavy chain antibody. Antibodies 
from camelids comprise two heavy chains (each of VHH, CH2 and CH3) only. These antibodies lack the light 
chains and the CH1 domain. Antigen binding occurs through one domain only, the VHH domain. Figure modified 
from Rothbauer et al., 2006. 
1.3.2 Genetic background of functional heavy chain antibodies 
The existence of functional hcAbs required some modifications in the composition of an 
antibody molecule in order to get along with the loss of the light chain. The first quite 
obvious modification is the deletion of the CH1 domain which is involved in the assembly 
process of heavy and light chains of classical antibodies. Heavy chains, after being 
synthesized, are retained in the endoplasmic reticulum by a chaperon called heavy-chain 
binding protein (BiP) until they associate with a light chain (Hendershot et al., 1987). The 
binding of BIP occurs at the CH1 domain. Only after the substitution of the BIP by the light 
chain, the antibody molecule can proceed towards its secretion. Hence, in hcAbs the 
absence of the CH1 domain enables the heavy chain to bypass this BIP capturing mechanism 
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without the need of being rescued by the light chain. The absence of the CH1 domain in 
hcAbs is caused by a mutation in the splice site immediately after the CH1 exon (Nguyen et 
al., 1999) (Woolven et al., 1999). These point mutations at the 3´ end of the CH1 are 
responsible for the removal of the CH1 encoding sequences by splicing during mRNA 
maturation (Nguyen et al., 2002).  
Compared to human VH domains, the VHH FRs show 80 % sequence homology 
(Muyldermans, 2001). However, in the FR2 region VHHs show four characteristic amino acid 
substitutions: Val37Phe or Val37Tyr, Gly44Glu, Leu45Arg or Leu45Cys and Trp47Gly (from VH 
to VHH; numbers refer to the amino acid positions numbered according to Kabat et al. 
(Kabat, 1991)) (Muyldermans et al., 1994) (see Figure 8). In classical antibody development 
these VH residues specifically interact with the VL domain via hydrophobic interactions. In the 
absence of a VL domain, these hydrophobic residues would likely cause unspecific 
aggregation of hcAbs, when this surface would be exposed to the aqueous environment. 
Hence, evolutionary conserved substitution of these VH residues by more hydrophilic 
residues in VHHs referred to as hallmark residues (Muyldermans et al., 1994), presumably 
lowers their tendency to interact with a VL domain (Muyldermans, 2001) and increase hcAb 
solubility. 
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Figure 8: Substitutions in amino acid sequence from VHs to VHHs. The numbering refers to the position of 
the amino acid along the sequence according to the Kabat numbering (Kabat, 1991). 
As already mentioned, camelids carry both conventional antibodies and hcAbs. 
Generally, the heavy chain variable domain (both VH and VHH) is encoded not only by one 
but multiple gene segments (Hozumi and Tonegawa, 1976) (Tonegawa, 1983) (Delves and 
Roitt, 2000): the V (variable) gene segment, the J (joining) gene segment and the D (diversity) 
gene segment (Schilling et al., 1980). During B cell differentiation, the gene segments are 
specifically ligated in a process called VDJ recombination to form a complete heavy chain 
variable exon (Tonegawa, 1983) in which the V gene segment encodes the CDR1 and CDR2, 
while the CDR3 is generated by the joining of the three gene segments. In order to achieve 
the amino acid substitutions which are specific for VHHs, camelid heavy chains do not arise 
from the same V genes as classical antibodies (Nguyen et al., 1999). VHHs are encoded by a 
distinct set of V segments (~40 V segments) resulting in the replacement of specific amino 
acids in the hydrophobic part which in classical antibodies interacts with the VL by 
hydrophilic amino acids (see Figure 9) (Nguyen et al., 2000). 
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Figure 9: Schematic illustration of VDJ-recombination of the heavy chain locus of heavy chain antibodies 
(VHH). The heavy chain V regions are assembled from three gene segments. First, the diversity (D) and J 
segments join which are used for conventional antibody recombination, as well. Then, the V gene segment 
which is specific for VHHs joins to the DJ segment resulting in a complete VHH exon. The number of gene 
segments in each region is shown in parentheses. 
The existence of only one heavy chain variable fragment may raise the question how the 
repertoire of VHHs is diversified since the random pairing of VH and VL in higher vertebrates 
further enhances diversification. First, the antibody repertoire in camelids is increased by the 
expansion of V gene segments having acquired VHH characteristics as described above. 
Second, hcAbs show more hotspots for somatic hypermutation in the VHH CDR1 region 
making this region more variable (Nguyen et al., 2000). The process of somatic 
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hypermutation (SHM) occurs in activated B cells after finishing gene rearrangements by VDJ 
recombination (Honjo et al., 2002). SHM alters the DNA sequence of secreted 
immunoglobulins and further enhances the affinity of the antibody repertoire by introducing 
point mutations at high rate into the V regions, preferentially into CDRs (Wu et al., 1979). 
The frequency of mutations in the V region is approximately 10-5 – 10-3/base pair/generation 
which is ~ 1 million-fold higher than the spontaneous rate of mutation in most other genes 
(Rajewsky et al., 1987). However, the extent of SHM in hcAb V domains is much higher than 
in the classical VHs (Conrath et al., 2003). Third, CDR3s of VHHs are exceptionally long (up to 
17 amino acid residues in dromedary VHHs) compared to the length of CDR3s of 
conventional VHs (up to 11 amino acid residues in dromedary VHs) which might compensate 
part of the diversity that is provided by the VL binding site in conventional antibodies 
(Conrath et al., 2003). This extended CDR3 is often stabilized by an additional disulfide bond 
cross-linking the CDR3 and CDR1 in camel or CDR3 and CDR2 in llama (Wesolowski et al., 
2009). 
1.3.3 Unique features of VHHs 
VHHs have characteristics that are similar to those - or even exceed those - of classical 
antibodies. Several advantages result from their single-domain nature and small size of 
approximately 15 kDa such as rapid blood clearance and fast tissue penetration. In addition, 
when constructing phage display libraries, the single-domain nature of VHHs offers an 
advantage over conventional antibody Fab or scFv fragments. Since antigen binding occurs 
only through one domain which is encoded by one single exon, there is no need for random 
recombination of the VH and VL domains (Verheesen et al., 2006). 
Contrary to classical antibodies, VHHs have been found to be outstandingly stable. For 
instance, they not only show extreme thermal stability at high temperatures of up to 90°C 
(van der Linden et al., 1999) or after incubation for one week at 37°C (Arbabi Ghahroudi et 
al., 1997) and maintain their functionality in extremes of pH, in denaturing conditions and 
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even in the presence of proteases (van der Linden et al., 1999). Their stability at high 
temperature indicates that VHHs have a very good shelf-life and their stability in extremes of 
pHs enable them to survive under harsh conditions found in the stomach and to remain 
functional in the gut creating opportunities for oral delivery (Harmsen and De Haard, 2007). 
Furthermore, VHHs are naturally soluble in aqueous solutions and show a very low tendency 
to aggregate, likely due to the increased hydrophilicity of the residues in the FR2 region 
(Muyldermans, 2001). 
VHHs are suitable for large-scale production in bacterial systems or lower eukaryotes. For 
example the production process of VHHs is easily scalable in yeast expression systems with 
expression levels up to ten times higher than e.g. scFvs (Muyldermans et al., 2009). These 
production systems enable to produce VHHs in constant quality which is crucial for their use 
in diagnostics or therapy. 
VHHs have been shown to have a preference for binding into active sites of enzymes due 
to their CDR3 regions forming fingerlike extensions (Lauwereys et al., 1998) (De Genst et al., 
2006). Hence, VHHs are able to recognize epitopes which are barely recognized by classical 
antibodies (Lauwereys et al., 1998). Although they consist of just one single domain it has 
been shown, that VHHs bind their antigen specifically with nanomolar affinity (Muyldermans 
and Lauwereys, 1999). 
The single-domain nature of VHHs could, however, be disadvantageous for binding to 
small antigens. Peptides or haptens usually bind in a groove or cavity at the VH-VL interface 
(Harmsen and De Haard, 2007). Indeed, Lange et al. immunized llamas with clenbuterol and 
found conventional but not heavy chain antibodies against this hapten (Lange et al., 2001). 
Still, VHHs recognizing peptides or haptens have been successfully isolated (Spinelli et al., 
2000) (Ladenson et al., 2006) (Harmsen et al., 2007). 
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1.3.4 Applications of VHHs 
Owing to their unique biochemical characteristics and robustness, VHHs are attractive 
reagents for a variety of diagnostic and therapeutic applications. So far, fast and reliable in 
vivo diagnosis of cancer at an early stage of disease progression remains a major challenge. 
Ideally, a cancer-imaging agent should visualize the smallest cancer-associated tissues with 
low levels of unspecific background. Due to fast blood clearance and good tissue penetration 
VHHs appear to be promising tools for such in vivo imaging approaches. It was shown that a 
nanobody specifically recognizing lysozyme targeted tumours transgenic for lysozyme 
(Revets et al., 2005). Furthermore, in cancer diagnostic tests (e.g. prostate cancer) VHHs are 
able to differentiate between different isoforms of prostate-specific antigen (PSA) and hence 
discriminate different stages of prostate cancer (Saerens et al., 2004).  
Besides diagnostic applications for in vivo imaging, VHHs have proven useful as specific 
drug delivery vehicles in tumor targeting (Cortez-Retamozo et al., 2004). Due to their small 
size they are able to reach hidden antigens delivering the toxic load to the cancerous tissue 
while healthy cells stay unharmed. Further potential therapeutic areas include inflammation, 
pulmonary diseases and neurology (Roovers et al., 2007) (Cortez-Retamozo et al., 2004) 
(Coppieters et al., 2006) (Ablynx, 2012). 
1.3.4.1 Chromobodies and Nanotraps 
Besides therapeutic and diagnostic approaches, VHHs are versatile tools for biomedical 
research. With the rapid expansion of proteomic studies there is a need for the generation 
of highly specific binding reagents to study the vast number of proteins encoded by the 
genome (He and Khan, 2005). As recombinant produced and purified protein, VHHs can be 
chemically coupled to beads (Rothbauer et al., 2008), matrices (Pichler et al., 2012) and chip 
surfaces to specifically extract antigens of interest from crude solutions for detection or 
more complex downstream analysis such as enzymatic activity assays or protein-protein 
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interactions. Accordingly, in such in vitro-based format, VHHs are termed Nanotraps (see 
Figure 10). Nanotraps are widely used in high-throughput proteomics and the manipulation 
of proteins (Trinkle-Mulcahy et al., 2008) (Webby et al., 2009) (Kirchhofer et al., 2010).  
In 2006 it has been shown that VHHs are not only valuable tools in biochemical assays but 
may also be used for dynamic antigen detection in living cells and thus enable a novel mode 
of subcellular analysis (Rothbauer et al., 2006). In modern live cell biology, fluorescent fusion 
proteins are used to study the spatiotemporal dynamics of a given protein of interest. For 
this purpose, fluorescent proteins (e.g. green fluorescent protein, GFP (Tsien, 1998)) are 
fused to the N- or C- terminus of the protein of interest. However, this fusion might result in 
masking of important domains of the protein. In addition, artificial introduced fluorescent 
fusion proteins are overexpressed in the cell and may behave differently from their 
endogenous counterparts who remain invisible (Chalfie et al., 1994) (Leonhardt et al., 1998). 
To detect and visualize endogenous proteins, antibodies are used as 
immunofluorescence reagents. For this purpose, however, the cells to be analyzed have to 
be fixed and permeabilized so that exogenously added, fluorescently labeled antibodies may 
enter the cells to bind and visualize their antigens. In contrast to classical antibodies, which 
are not functional in living cells, VHHs are small and stable enough to maintain their antigen 
binding function even in the reducing environment of the cell. Thus, genetic fusion of a VHH 
with a fluorescent protein (see Figure 10) enables antibody-mediated detection of 
endogenous proteins in live cells (Rothbauer et al., 2006). As a consequence, these so-called 
Chromobodies combine features of recombinant fluorescent fusion proteins and antibody-
based detection and may provide data about mobility and dynamics of endogenous proteins 
localized in different subcellular compartments.  
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Figure 10: Chromobody and Nanotrap. Chromobodies result from the genetic fusion of the VHH domain 
with a fluorescent protein. VHHs coupled to immobilizing matrices are termed Nanotraps. Modified after 
Rothbauer et al., 2006. 
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1.4 Aims and Objectives 
Antibodies are powerful tools in biomedical research, diagnostics and therapy. However, 
they have many drawbacks due to their size and complex structure. Naturally occurring 
heavy chain antibodies of camelids recognize and bind their antigens through one domain 
only, the VHH domain. The unique features of VHH domains enable to circumvent the 
drawbacks of classical antibodies not only through their small size but also through their 
single-domain nature. The work presented in this thesis focuses on the generation and 
characterization of antigen specific VHHs. 
The aim of this work is to use the non-conventional immune system of alpacas to 
generate functional VHHs against different antigens ranging from fullength proteins to 
domains and peptides. These VHHs are analyzed, characterized and compared in terms of 
their in vitro and in vivo functionality. However, specific VHHs are not easily obtained. In the 
course of this work optimization in library generation and phage display methods are 
performed. Adjustments in the generation process of VHH libraries are necessary since the 
quality concerning size and diversity is crucial to obtain specific VHHs. Phage display needs to 
be adjusted not only with regards to the corresponding antigen, protein or peptide, but also 
to the application of VHHs - intracellular or for in vitro studies. 
The methodology behind this work will be described in chapter 2 and the results will be 
presented in chapter 3 followed by a discussion in chapter 4. 
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2 Materials and Methods 
2.1 Material 
2.1.1 Consumables 
Table 1: Applied consumables. 
CONSUMABLE MANUFACTURER 
Adhesive Film, aluminium, 96W VWR International, Ismaning, Germany 
Amicon® Ultra Centrifugal Filter Devices Millipore S.A.S., Molsheim, France 
Assay Block, 96 well, 2 ml Schubert & Weiss, Munich, Germany 
Cell Culture Plates, p100 Schubert & Weiss, Munich, Germany 
Coverslips 18 x 18 x 0.17 mm Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Cryotubes, 1,8 ml Nunc GmbH, Wiesbaden-Biebrich, Germany 
Desalting Column PD-10 GE Healthcare, Uppsala, Sweden 
ECL (enhanced chemiluminescence) AG Böttger, LMU Munich, Germany 
Electroporation cuvettes Bio-Rad Laboratories GmbH, Munich, Germany 
Falcon Tubes (15 und 50 ml) Sarstedt AG & Co., Nümbrecht, Germany 
Film Super RX 100 NIF 13x18 
FUJIFILM PHOTO FILM EUROPE GMBH, 
Dusseldorf , Germany 
Filtorpur S 0.45 Sarstedt AG & Co., Nümbrecht, Germany 
Filtropur S 0.2 Sarstedt AG & Co., Nümbrecht, Germany 
First-Strand cDNA Synthesis Kit GE Healthcare, Uppsala, Sweden 
GFP-multiTrap ChromoTek GmbH, Martinsried, Germany 
Größenstandard DNA (Smart Ladder) EUROGENTEC s.a., SERAING, Belgium 
GST-Trap FF column, 1 ml GE Healthcare, Uppsala, Sweden 
HiTrap™ HP column, 1 ml GE Healthcare, Uppsala, Sweden 
Immuno Plates Maxisorp C 96 Thermo Scientific GmbH, Schwerte, Germany 
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Immunotubes Nunc-Immuno, Polystyrene 
StarTube, MaxiSorp 
Thermo Scientific GmbH, Schwerte, Germany 
Ligation-Kit 
1. T4 DNA Ligase (400,000 units/ml) 
2. 10x T4 DNA Ligase Reaction Buffer (500 
mM Tris-HCl ; 100 mM MgCl2 ; 10 mM 
ATP ; 100 mM Dithiothreitol ; 250 
µg/ml BSA ; pH 7,5) 
New England Biolabs, Ipswich, England 
Midiprep System PureYield Plasmid Promega GmbH, Mannheim, Germany 
Microscope Slides VWR International, Ismaning, Germany 
µClear 96-well microplate Greiner Bio-One, Frickenhausen, Germany 
µ-slide( I or IV) Ibidi GmbH, Martinsried, Germany 
Multiwell plate,  6 well, steril Nunc GmbH, Wiesbaden-Biebrich, Germany 
Nitrocellulose Membrane Bio-Rad Laboratories GmbH, Munich, Germany 
NucleoSpin Gel and PCR Clean-up Kit Macherey-Nagel, Düren, Germany 
NucleoSpin RNA XS Macherey-Nagel, Düren, Germany 
Parafilm Brand GmbH & Co. KG, Wertheim, Germany 
PCR-Reaction tube, 200 µl/500 µl Sarstedt AG & Co., Nümbrecht, Germany 
PD-10 desalting column GE Healthcare, Uppsala, Sweden 
Petridish, 92 x 16 mm Sarstedt AG & Co., Nümbrecht, Germany 
Petridish, 145 x 20 mm Greiner Bio-one, Frickenhausen, Germany 
pH Indicatorstrips, pH 0-14 Merck KGaA, Darmstadt, Germany 
Pipettes (2, 5, 10 und 25 ml) Sarstedt AG & Co., Nümbrecht, Germany 
Pipettetips (10, 20, 200, 1000, 1250 µl) Sarstedt AG & Co., Nümbrecht, Germany 
Reaction tube 1,5 ml / 2 ml (steril) Sarstedt AG & Co., Nümbrecht, Germany 
Superdex 75 10/300 GL GE Healthcare, Uppsala, Sweden 
UltraVette® UV-Küvetten Mikro, 70 – 850 µl Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
UNI-SepMAXI Lymphocyte Seperation Tubes Novamed Ltd., Jerusalem, Israel 
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Vaccumbottle without sodium citrate (250 ml) Evozone, Reutlingen, Germany 
2.1.2 Solutions and Chemicals 
Table 2: Applied solutions and chemicals. 
SOLUTIONS AND CHEMICALS MANUFACTURER 
1,4 Dithiothreitol (DTT)  
Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
2-Propanol Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
2x YT Medium (2xYT) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
3,3’,5,5’-Tetramethylbenzidin (TMB) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Acetic Acid, 99-100% Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Agarose, molecular biology grade 
Serva Electrophoresis GmbH, Heidelberg, 
Germany 
Ammoniumperoxodisulfat (APS) Carl Roth GmbH + Co KG, Karlsruhe 
Ampicillin AppliChem GmbH, Darmstadt, Germany 
ATTO dyes (NHS Ester) ATTO-TEC GmbH, Siegen, Germany  
-Mercaptoethanol   
BSA Sigma-Aldrich Chemie Gmbh, Munich, Germany 
Coomassie Brilliant Blue G250 
Serva Electrophoresis GmbH, Heidelberg, 
Germany 
DAPI (4,6-diamiddino-2-phenylindole) Roche Diagnostics GmbH, Mannheim, Germany 
DMEM, high Glucose 
Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
di-sodium hydrogen phsophat Merck KgaA, Darmstadt, Germany 
DMSO 100% Finnzymes Oy, Espoo, Finland 
Dnase I Diagonal GmbH, Münster, Germany 
dNTP-Set (dATP, dCTP, dGTP, dTTP, pH 7.5) 
PEQLAB Biotechnologie GmbH, Erlangen, 
Germany 
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EDTA AppliChem GmbH, Darmstadt, Germany 
Ethanol, absolut 
Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Ethanol, denatured Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ethidiumbromid-Solution (0,025 %) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Fluorescein isothiocyanate (FITC) Thermo Scientific GmbH, Schwerte, Germany 
Formaldehyde (37%) 
Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
FCS ”Gold“ PAA Laboratories GmbH, Cölbe, Germany 
Gentamycin (50 mg/ml) PAA Laboratories GmbH, Pasching, Austria 
Gerbu Pharma Adjuvant Gerbu Biotechnik GmbH, Heidelberg, Germany 
Glucose D(+) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Glycine Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Heparin Natrium 25.000 Ratiopharm GmbH, Ulm, Germany 
Hydrochloric acid 37% AppliChem GmbH, Darmstadt, Germany 
Hydrogen Peroxide Fluka Chemie AG, Germany 
Hyperphage (M13K07ΔpIII) Progen Biotechnik GmbH, Heidelberg, Germany 
Imidazol 
Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Isopropyl-beta-D-thiogalaktopyranosid (IPTG) Diagonal GmbH, Münster, Germany 
Kanamycin  
Lipofectamin 2000 Life Technologies GmbH, Darmstadt, Germany 
LSM 1077 Separation Solution for Lymphocytes PAA Laboratories GmbH, Pasching, Austria 
Luria Broth (LB) Medium Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Lysozyme  
Magnesium chloride Sigma-Aldrich Chemie Gmbh, Munich, Germany 
Methanol, min. 99 % Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Milkpowder, Blotting Grade Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
NHS-activated SepharoseTM 4 Fast Flow GE Healthcare, Uppsala, Sweden 
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PageRuler™ Prestained Protein Ladder/ 
PageRuler™ Prestained Protein Ladder Plus 
Fermentas GmbH, St.Leon-Rot, Germany 
PEI, pH 7/pH10 A. Gahl, LMU Munich, Germany 
Phosphate Buffered Saline (PBS), 1x 
Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Phusion™ High-Fidelity DNA Polymerase 
New England Biolabs GmbH, Frankfurt, 
Germany 
Pierce protein free blocking buffer Thermo Scientific GmbH, Schwerte, Germany 
Protease Inhibitor Mix M 
SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
Polyacrylamide Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Restrictionenzymes 
New England Biolabs GmbH, Frankfurt, 
Germany 
Phenylmethanesulfonylfluoride (PMSF) 
SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
Ponceau S Sigma-Aldrich Chemie Gmbh, Munich, Germany 
Potassium chloride Sigma-Aldrich Chemie Gmbh, Munich, Germany 
RNase A (10 mg/ml)  
Select Agar Invitrogen GmbH, Karlsruhe, Germany 
Smart Ladder / Smart Ladder SF DNA Standard Eurogentec, Seraing, Belgium 
Sodium bicarbonate 
Sigma-Aldrich Chemie Gmbh,  Steinheim, 
Germany 
Sodium carbonate 
Sigma-Aldrich Chemie Gmbh, Steinheim, 
Germany 
Sodium chloride Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Sodium dodecyl sulfate pellets (SDS) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Sodium hydroxide pellets  
Sulfuric acid, 96 % Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
TEMED Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
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Tris (trisaminomethane) Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Triton X-100 Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
TRIzol Reagent Life Technologies, Carlsbad, USA  
Trypsin/EDTA (1:250) PAA Laboratories GmbH, Cölbe, Germany 
Tween 20 Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Vectashield Mounting Medium Vector Larboratories Inc., Burlingame, USA  
2.1.3 Instruments 
Table 3: Applied instruments. 
INSTRUMENT MANUFACTURER 
Agarosegelsystem (Mupid) 
Bangkok Advanced Technologx Co., Bangkok, 
Thailand 
ÄKTA purifier FPLC-system GE Healthcare, Uppsala, Sweden 
Balance BL 1500S Sartorius AG, Göttingen, Germany 
Digital Sonifer Model 450-D Branson 
DU® 730 Life Science UV/Vis 
Spectrophotometer 
Beckman Coulter 
Electroporator Bio-Rad Laboratories GmbH, Munich, Germany 
Epifluorescence microscope Axiovert 135 TV Zeiss, Jena, Germany 
Film developping machine CP1000 AGFA 
Geldocumentation system FluorChem 8900 Alpha Innotech Corporation, San Leandro, USA 
InCell Analyzer 1000 GE Healthcare, Uppsala, Sweden 
Incubator for bacteria Heraeus 
Infinite M1000 Plate reader Tecan Group Ltd., Männedorf, Switzerland 
NanoVue Plus Spectrophotometer 
GE Healthcare Biosciences AB, Uppsala, 
Sweden  
Proteingel apparatus Mini-Protean II Bio-Rad Laboratories GmbH, Munich, Germany 
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Shaker for bacteria cultures, Certmonat H+R B. Braun 
Speedvac RVC 2-18 
Martin Christ Gefriertrocknungsanlagen GmbH, 
Osterode, Germany 
Tabletop centrifuge Mikro 22 R Hettich Zentrifugen,  
Tabletop centrifuge CR 4.12 Jouan GmbH, Fernwald, Germany 
Thermocycler Mastercycler gradient Eppendorf AG, Hamburg, Germany 
Thermoshaker Thermomixer comfort Eppendorf AG, Hamburg, Germany 
Trans-Blot SD Blotting aparatus Bio-Rad Laboratories GmbH, Munich, Germany 
Ultracentrifuge Centrikon H-401 Kontron Hermle 
2.1.4 Cell lines 
Table 4: Applied cell lines. 
CELL LINE TYPE 
HeLa Kyoto Human cervical carcinoma cell line 
HEK293T Human embryonic kidney cell line  
BHK clone #2 
Transgenic baby hamster kidney cell line 
containing a lac operator array (Tsukamoto et 
al., 2000) 
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2.1.5 Antibodies 
Table 5: Applied primary antibodies. 
ANTIBODY (SPECIES) MANUFACTURER 
Anti-His6 (C-term) (mouse) GE Healthcare,Uppsala, Sweden 
Anti-His6 (C-term)-HRP (mouse) Invitrogen GmbH, Karlsruhe, Germany 
Anti-Dnmt1 (rat) Dr. Elizabeth Kremmer, Munich, Germany 
Anti-GFP (mouse) Roche Diagnostics GmbH, Mannheim, Germany 
Anti-GST (rat) Dr. Elizabeth Kremmer, Munich, Germany 
Anti-PCNA (rat) Dr. Elizabeth Kremmer, Munich, Germany 
Table 6: Applied secondary antibodies. 
ANTIBODY (SPECIES) MANUFACTURER 
HRP/Anti-M13 Monoclonal Conjugate (mouse) GE Healthcare, Uppsala, Sweden 
Anti-mouse-HRP (sheep) GE Healthcare, Uppsala, Sweden 
Anti-goat-HRP (rabbit) Zymed GmbH, Vienna, Austria 
Anti-rat-HRP (goat) Dianova 
Anti-rat-Alexa Fluor 647 Conjugate Cell Signaling Technology,  
Llama IgG-heavy and light chain antibody HRP 
conjugated 
Bethyl Laboratories Inc, Montgomery, USA 
2.1.6 Primer 
Primer used for polymerase chain reactions were synthesized by Metabion AG 
(Martinsried, Germany). To amplify the VHH-repertoire of an alpaca from the cDNA derived 
from peripheral B cells the following primer were used. 
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Table 7: Primer used for amplification of VHHs. 
PRIMER SEQUENCE 
Call 001 5´- GTC CTG GCT GCT CTT CTA CAA GG-3´ 
Call 002 5´- GGT ACG TGC TGT TGA ACT GTT CC-3´ 
SM017 5´- CCA GCC GGC CAT GGC TCA GGT GCA GCT GGT GGA GTC TGG-3’ 
SM018 5´- CCA GCC GGC CAT GGC TGA TGT GCA GCT GGT GGA GTC TGG-3‘ 
A4-short 5´- CAT GCC ATG ACT CGC GGC CCA GCC GGC CAT GGC-3´ 
38 reverse 5´- GGA CTA GTG CGG CCG CTG GAG ACG GTG ACC TGG GT-3’ 
2.1.7 Bacterial strains 
Different bacterial strains (Table 8) were used according to the intended application. For 
the production of phage particles and the generation of phage-libraries, the E. coli strain TG1 
was used. This strain is a so called “suppressor strain” and encodes for an additional 
transfer-RNA which recognizes the Amber stop codon (TAG). Hence, instead of the 
termination of the protein synthesis glutamate is incorporated in the polypeptide chain. 
JM109 and BL21 cells were used for protein expression. XL-1 Blue cells were used for 
cloning work. 
Table 8: Bacterial strains 
STRAIN MANUFACTURER 
Chemical-Competent  E. coli JM109  
Chemical-Competent E. coli XL-1 Blue 
Agilent Technologies GmbH & Co.KG, Waldbronn, 
Germany 
Chemical-Competent E. coli BL21 Life Technologies 
Electroporation-Competent E. Coli  TG1 
Agilent Technologies GmbH & Co.KG, Waldbronn, 
Germany  
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2.2 Methods 
2.2.1 Molecular biological Methods 
2.2.1.1 Culturing of bacteria 
Culturing of bacteria was conducted in LB-Medium or 2xYT-Medium at 37°C in an 
incubator shaker. The appropriate antibiotic was added according to the antibiotic resistance 
gene encoded by the respective plasmid. 
The optical density of the culture was measured at 598 nm (OD598) with an UV/Vis 
spectrophotometer (DU® 730 Life Science UV/Vis, Beckman Coulter). 
2.2.1.2 Cryoconservation of bacterial cultures 
For long-term storage (-80°C) of bacterial cultures glycerol stocks were made with 15% 
(w/v) final concentration glycerol. 
2.2.1.3 Transformation of competent E. coli cells 
Chemical-competent JM109 and XL-1 Blue cells were transformed by heat-shock 
transformation: ~ 50 ng plasmid DNA or 5 µl ligation was added to the bacteria and 
incubated 30 min on ice following a heat shock at 42°C for 30 s. After 2 min incubation on ice 
100 µl SOC-Medium (20 g bacto tryptone, 5 g yeast extract, 0,5 g NaCl, ad 1 l ddH2O, 10 mM 
MgCl2, 10 mM MgSO4, 397 µl 50 % Glucose) was added and incubated at 37°C/200 rpm for 1 
h. The whole bacteria suspension was applied on to an agar plate containing the appropriate 
antibiotic and was incubated at 37°C over night. 
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2.2.1.4 Preparation of Plasmid-DNA 
Depending on the intended application and necessary amount of plasmid DNA two 
different methods were applied to prepare plasmid DNA. 
For sequence analysis and cloning procedures plasmid DNA was prepared by alkaline 
lysis. After genomic DNA, cell debris and proteins are separated plasmid DNA was 
precipitated with ethanol. The DNA pellet was dried and resuspended in 40 µl H2O. 
For the preparation of plasmid DNA for transfections, the Midiprep System PureYield 
Plasmid (Promega) was used according to the manufacturer’s protocol. 
2.2.1.5 Quantification of DNA 
The concentration of DNA was measured spectrophotometric (NanoVue Plus, GE 
Healthcare; absorbance 260 nm). 
2.2.1.6 Polymerase chain reaction 
Polymerase chain reaction (PCR) was used to amplify DNA fragments and to introduce 
restriction sites via primers for a subsequent cloning step if required. A typical amplification 
reaction includes the sample of template DNA, two oligonucleotide primers, 
deoxynucleotide triphosphates (dNTPs), reaction buffer and the thermostable DNA Phusion-
polymerase (Table 9). PCR results in the exponential synthesis of a distinct DNA sequence by 
repeated denaturing, hybridization and extension cycles with 25-30 cycles usually carried out 
(Table 10).  
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Table 9: Exemplary PCR-preparation scheme. 
COMPONENT AMOUNT/VOLUME FINAL CONCENTRATION 
Template DNA 50 ng 50 ng 
Forward primer (c= 10 pmol/µl) 1  µl 0,2 µM 
Reverse primer (c= 10 pmol/µl) 1 µl 0,2 µM 
5x Phusion buffer 10 µl 1x 
dNTP mix (c= 
10mM/nucleotide) 
1 µl 200 µM/nucleotide 
Phusion Polymerase 1 µl 0,08 U/µl 
ddH2O ad 50 µl  
Table 10: Exemplary PCR program 
STEP TEMPERATURE TIME NUMBER OF CYLCES 
Initial denaturing 94°C 30 s 1 
Denaturing 94°C 15 s  
Annealing 58°C 15 s 25-30 
Extension 72°C 20 s  
Final extension 72°C 7 min 1 
 4°C ∞  
2.2.1.7 DNA restriction digestion 
For restriction digestion of DNA fragments or plasmid DNA endonucleases from New 
England Biolabs were used and restriction digestion was performed following the 
manufacturer´s protocol.  
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2.2.1.8 Agarose gel electrophoresis with DNA 
Agarose gel electrophoresis enables the user to monitor the PCR procedures or 
restriction digestions, but also to size fractionate DNA molecules in order to purify these 
from the gel. Agarose gel electrophoresis was performed in 0,5x Tris-Acetate-EDTA-buffer 
(TAE-buffer) with agarose concentrations of 0,8% (w/v), 1,0% (w/v) or 1,5% (w/v). DNA was 
detected by ethidium bromide (EtBr) (final concentration: 0,025 µg/ml). As standard, the 
markers SmartLadder or SmartLadder SF (Eurogentec) were used. After electrophoresis the 
gel was placed on an UV light box and the fluorescent ethidium bromide-stained DNA 
pictured using the imaging system FluorChem 8900 (Alpha Innotech Corporation). 
2.2.1.9 DNA purification from agarose gels 
DNA fragments visualized on an UV light box were removed from the gel by the use of 
scalpels. Once captured, the DNA was eluted from the jellified agarose following the 
instructions of the NuceloSpin® Extract II-Kit (Macherey-Nagel). Elution volume was 30 µl. 
2.2.1.10  DNA Ligation 
Purified and restriction enzyme-treated DNA fragments were ligated into the desired 
plasmid vectors, which also have been treated with the respective endonucleases producing 
compatible overhangs. After the vector and insert DNA have been prepared and their 
concentration determined via agarose gel electrophoresis a 1:3 molar ratio of vector and 
insert was used for the reaction (Table 11). All ligations were performed with ATP-
dependent T4 DNA ligase and the provided buffer (New England Biolabs) either 4 hours at 
room temperature or overnight at 16°C. Following the reaction, the ligated DNA was 
transformed into an appropriate host strain, E. coli JM109 or XL-1 Blue as described in 
2.2.1.3. 
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Table 11: Exemplary ligation preparation. 
COMPONENT AMOUNT/VOLUME FINAL CONCENTRATION 
10x T4 Ligase Buffer 1 µl 1x 
T4 DNA ligase 1  µl 1 U 
DNA Vector 1 µl 0,025 pmol 
DNA Insert 1 µl 0,076 pmol 
ddH2O ad 10 µl  
2.2.1.11  DNA sequencing 
The sequencing of DNA was performed by MWG, Ebersberg.  
2.2.2 Cell Culture Methods  
2.2.2.1 Cultivation of mammalian cells 
Cell culture was carried out in a sterile bench applying sterile working techniques. If not 
indicated else, cells were cultivated in DMEM supplemented with 10% fetal calf serum at 
37°C, 5% CO2 and 95% humidity. Subconfluently grown cells were passaged every 2-3 days 
with trypsin/EDTA. 
2.2.2.2 Seeding of cells 
For microscopic experiments cells were seeded at appropriate density (40-60% 
confluence) either on 18 x 18 glass cover slips in a 6-well plate (Nunc) or for high-throughput 
screens in µClear 96-multiwell plates (Greiner). 
For the production of cell extracts from HEK293T cells, they were seeded 1:3 in p100 cell 
culture dishes. 
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2.2.2.3 Transfection of plasmids 
In general, cells were transfected 4-6 h after seeding. For imaging of fixed samples on 
cover slips, 4 µg plasmid DNA, 16 µl PEI pH 10 (polyethylenimin) and 150 µl pure DMEM 
(without serum) was incubated 10-15 min at room temperature and added to the cells. After 
4 – 6 h the medium was replaced by fresh medium and the cells were incubated over night. 
For high-content imaging in 96-well plates, the reverse Lipofectamine 2000 transfection 
protocol as provided by the manufacturer (Life Technologies) was applied. In brief, the 
transfection mix containing 0.1 µg DNA and 0.2 µl Lipofectamine 2000 was prepared in 50 µl 
pure DMEM (without serum) per well. Cells were seeded on top (after 20 minutes 
incubation) and transfection takes place over night.  
For the transfection of HEK293T cells in p100 cell culture dishes 72 µl transfection 
reagent PEI pH 7, 24 µg plasmid DNA and 600 µl pure DMEM (without serum) was incubated 
10-15 min at room temperature and added to the cells. The cells were incubated over night. 
2.2.2.4 Fixation of cells 
For fixation cells were washed twice with 1x PBS and fixed with 3,7% formaldehyde in 
PBS for 15 min at room temperature. The fixation solution was discarded and exchanged 
with PBS followed by two washing steps with 0,02% Tween20 in PBS (PBST). Cells were 
permeabilized and counterstained for 5-10 min with 0,2% Triton X-100 in PBST and 0,02 
µg/ml 4,6-diamidino-2-phenylindole (DAPI). After another washing step (3x with PBST), 
cover slips were mounted in Vectashield (Vector Laboratories). Multiwell plates are stored in 
PBST at 4°C. 
2.2.2.5 Microscopy 
Fixed cells expressing fluorescent fusion proteins were analyzed by wide-field 
epifluorescence microscopy (Axiovert 135 TV, Zeiss). F2H images were acquired on the InCell 
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analyzer 1000 (GE Healthcare). An automated segmentation analysis protocol was previously 
established. Interactions were verified through manual inspection.  
2.2.3 Biochemical Methods 
2.2.3.1 Expression and purification of recombinant proteins from E. coli 
2.2.3.1.1 Induction of protein expression in E. coli 
All proteins (VHH domains, antigens for immunization/screening) were expressed in E. 
coli. under the control of the lac-promotor. The lac-operon is induced by lactose only 
temporary since lactose is metabolized by the bacteria. In order to achieve a constant 
activity of the lac-operon, the structural analog Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
is used. IPTG binds, the same way as lactose, to the lacI repressor, inactivates it and in that 
way hinders its binding to the lac-operator. However, the bacteria cannot metabolize it 
resulting in a constant induction of the lac-promotor and hence in the expression of the 
fusionprotein. 
In brief, bacteria cultures were grown at 37°C until OD598 0,7-0,9 was reached. Protein 
expression was induced by adding 0,5 mM IPTG. Proteins were expressed overnight at room 
temperature. Bacteria were harvested by centrifugation at 5000 rpm for 10 min at 4°C. 
Afterwards pellets were stored at -20°C or resuspended in binding buffer (his-tagged 
proteins: 1x PBS, 0,5 M NaCl, 20 mM imidazol, pH 8; GST-tagged proteins: 1x PBS, 1 mM DTT) 
and further processed. 
2.2.3.1.2 Lysis of bacteria 
Bacteria were lysed in binding buffer plus protease inhibitor 
phenylmethanesulfonylfluoride (PMSF) (0,5 mM) by adding lysozyme (0,1 mg) with 
subsequent sonification (20 sec maximum amplitude, 20 sec break, repeat 6x). Insoluble 
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components and non-lysed cells were separated by centrifugation. Supernatant was filtrate 
through a 0,45 µm filter. 
2.2.3.1.3 Purification of proteins using affinity chromatography 
Proteins were purified using affinity chromatography via the hexahistidine-peptide his-
tag and Ni2+ sepharose or the gluthatione S-transferase. All purifications were performed 
using the ÄKTA purifier FPLC-system (GE Healthcare) and 1 ml HisTrap HP columns (GE 
Healthcare) with flow rate of 1 ml/min or 1 ml GST-Trap FF columns (GE Healthcare) with 
flow rate of 0,5 ml/min. The HisTrap columns were equilibrated with 5 column volumes in 
binding buffer (1x PBS, 0,5 M NaCl, 20 mM imidazol, pH 8). Bound proteins were eluted in 1 
ml fractions by adding elution buffer with higher imidazol concentrations (1x PBS, 0,5 M 
NaCl, 500 mM imidazol, pH 6,8). The GST-Trap FF columns were equilibrated with 5 column 
volumes in binding buffer (1x PBS, 1 mM DTT). Bound proteins were eluted in 1 ml fractions 
by adding elution buffer (200 mM NaCl, 15 mM glutathione, 50 mM Tris pH 9, 2 mM DTT). 
2.2.3.1.4 Gel filtration chromatography 
Gel filtration chromatography was performed using the ÄKTA purifier FPLC-system and a 
Superdex 75 gelfiltration column. The flow rate of all steps was 0,5 ml/min. The column was 
equilibrated with two column volumes with 1x PBS. Peak fractions of the affinity 
chromatography eluate were pooled and maximal 2 ml of the eluate was applied to the 
column. Proteins were collected in 0,5 ml fractions. 
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2.2.3.2 SDS-PAGE 
Proteins were separated by SDS-PAGE according to Table 12. 
Table 12: Composition of separation gel and stacking gel for SDS-PAGE. 
GEL COMPONENTS 
Separation gel 
8-12% (w/v) Acrylamide; 0,08-0,3% (w/v) 
Bisacrylamide; 375 mM Tris/HCl pH 8,8; 0,1% SDS, 
0,05% (w/v) APS, 0,05% (v/v) TEMED 
Stacking gel 
5% (w/v) Acrylamide; 0,033% (w/v) Bisacrylamide; 60 
mM Tris/HCl pH 6,8; 0,1% SDS, 0,05% (w/v) APS, 
0,1% (v/v) TEMED 
2.2.3.3 Coomassie staining 
SDS gels were Coomassie stained according to the manufacturer´s protocol. 
2.2.3.4 Western Blot 
Proteins were transferred from SDS-gels to nitrocellulose membranes (Bio-Rad) by semi-
dry blotting. Transfer was carried out at 240 mA. The membrane was incubated for 1h in 3% 
milk powder in Tris buffered saline with 0,075% Tween-20 (TBST) at room temperature and, 
subsequently incubated with the primary antibody diluted in 3% milk-TBST at 4°C over night. 
The membrane was washed 3 times in TBST for 5 min to remove unbound antibodies. 
Binding of the secondary antibody was performed diluted in 3% milk-TBST for 1 h at room 
temperature. The membrane was washed 3 times with TBST for 5 min. The membrane was 
than either treated with ECL-solution (if HRP-conjugated secondary antibody was used) and 
bound proteins were detected on a film or were detected with the Image Quant software on 
a Typhoon Scanner. 
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2.2.3.5 Chemical labeling 
In order to use recombinant VHHs in immunofluorescence they were labeled with 
Fluorescein isothiocyanate (FITC) (Thermo Scientific) or ATTO-fluorescent dyes (ATTO-TEC) 
via N-Hydroxysuccinimide (NHS) according to the manufacturer´s protocols. Labeled proteins 
and free fluorescent dyes were separated using PD-10 desalting columns (GE Healthcare). 
2.2.3.6 Dot blot 
Dot blot analysis was performed to map the epitope of an antigen specific VHH. 2 µg of 
peptide or recombinant protein were spotted on nitrocellulose and incubated with FITC 
labeled VHHs. The binding signals were obtained by scanning on a Typhoon Scanner and 
normalized against the background. Quantification of the signals was performed with the 
Image Quant software on a Typhoon Scanner. Peptides were solved either in 1x PBS or 
DMSO. 
2.2.3.7 Coupling of VHHs to NHS-Sepharose 
Purified VHHs were covalently coupled to Sepharose beads (GE Healthcare) via NHS 
according to the manufacturer´s protocol. 
2.2.3.8 Immunoprecipitation using mammalian cells 
For one immunoprecipitation reaction ~107 HEK293T cells were resuspended in lysis 
buffer (20 mM Tris/Cl pH7,5, 150 mM NaCl, 0,5 mM EDTA, 0,5% NP-40) plus 1 mM PMSF, 1x 
protease inhibitor mix (Serva), 0,5 µg/µl DNase and 2,5 mM MgCl2. The soluble fraction was 
separated by centrifugation and the supernatant was diluted with dilution buffer (20 mM 
Tris/Cl pH 7,5, 150 mM NaCl, 0,5 mM EDTA). 50 µl slurry of NHS-activated Sepharose beads 
covalently coupled with a VHH as described in 2.2.3.7 were equilibrated by washing 3 times 
with dilution buffer. HEK293T cell lysate was added to the equilibrated beads and incubated 
for 4 h at 4°C and subsequent SDS-PAGE analysis followed. 
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2.2.3.9 Immunoprecipitation using E. coli 
Bacteria expressing the appropriate protein were induced as described in 2.2.3.1.1. For 
one immunoprecipitation culture volume corresponding to an OD600nm of 0,5 was 
centrifuged and the pellet was resuspended in lysis buffer (20 mM Tris/Cl pH 7,5, 150 mM 
NaCl, 0,1% Triton X-100, 0,5 mM EDTA) plus 200 mM PMSF, 0,5 µg/µl DNase, 2,5 mM MgCl2 
and 0,1 mg/ml lysozyme and incubated 30 min on ice. The soluble fraction was separated by 
centrifugation and diluted with dilution buffer (20 mM Tris/Cl pH 7,5, 150 mM NaCl, 0,5% 
NP-40, 0,5 mM EDTA). 50 µl slurry of NHS-activated Sepharose beads covalently coupled 
with a VHH as described in 2.2.3.7 were equilibrated with dilution buffer as described in 
2.2.3.8. The lysate was added to the equilibrated beads and incubated over night at 4°C. The 
beads were washed twice with dilution buffer and subsequent SDS-PAGE analysis followed. 
2.2.3.10  Immunoprecipitation using recombinant protein 
Immunoprecipitation was performed as described in 2.2.3.9, but 20 µg of the 
appropriate recombinant protein was added instead of E. coli lysate.  
2.2.4 Immunological Methods 
In the course of this work libraries generated from immunized alpacas were used to 
select antigen specific VHHs. The alpacas were immunized with different antigens ranging 
from protein to peptide either produced recombinantly in E. coli or insect cells or 
synthesized (see Table 13). 
2 Materials and Methods 
 
55 
 
Table 13: Applied antigens. 
APPLIED ANTIGEN SOURCE 
yH2AX-KLH Synthesized by PSL GmbH 
HIV-1 CA E. coli (provided by Hans-Georg Kräußlich) 
PCNA E. coli (provided by M. Cristina Cardoso) 
ß-Catenin-GST E. coli (provided by Oliver Pötz) 
hDnmt1 Insect cells (provided by Carina Frauer) 
2.2.4.1 Immunization 
To generate immune VHH libraries, four alpacas Anna, Ferdl, Annabel and Sina were injected 
with antigen six to seven times. The immune response of the alpacas was enhanced by using 
Gerbu Pharma Adjuvant #3003 to guarantee a gentler immune reaction in comparison to 
Freud´s Adjuvants. The alpacas are kept at the “Lehr- und Versuchsgut der Tierärztlichen 
Fakultät” of the University Munich in a herd of ten animals. The immunizations were 
performed subcutaneous in the clean-shaven neck of the alpaca by Dr. Stefan Nüske.  
Alpaca Anna was immunized with γH2AX-KLH for 49 days following the immunization 
scheme depicted in Table 14. The same immunization scheme was used for the 
immunization of alpaca Ferdl immunized with non-infective HIV-capsid protein. 
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Table 14: Immunization scheme for alpaca Anna and Ferdl. Anna was immunized with γH2AX-KLH for 49 
days. Ferdl was immunized with non-infective HIV-capsid protein. 
DAY AMOUNT ANTIGEN (µG) 
0 500 
7 125 
14 125 
21 125 
35 125 
49 125 
Alpaca Annabel was immunized with PCNA for 103 days with immunization scheme 
depicted in Table 15. After 3 month rest period, Annabel was immunized with ß-Catenin-GST 
for 103 days with the same immunization scheme. 
Table 15: Immunization scheme for alpaca Annabel. Annabel was immunized with PCNA for 103 days. 3 
months later Annabel was immunized with ß-Catenin-GST for 103 days. 
DAY AMOUNT ANTIGEN (µG) 
0 500 
7 125 
14 125 
21 125 
35 125 
49 125 
103 125 
Alpaca Sina was immunized with hDnmt1 for 87 days with the immunization scheme 
depicted in Table 16. 
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Table 16: Immunization scheme for alpaca Sina. Sina was immunized with hDnmt1 for 87 days. 
DAY AMOUNT ANTIGEN (µG) 
0 600 
7 120 
14 120 
21 250 
35 250 
49 250 
87 250 
2.2.4.2 ELISA of preimmune and immune sera 
Before the first immunization and after a certain time period blood samples (100 ml) 
were taken from each alpaca. The blood was drawn by Dr. Stefan Nüske from the external 
jugular vein (Vena jugularis externa) of the alpaca in vacuum bottles (Evozone) pretreated 
with Heparin (Ratiopharm). Sera were generated by centrifugation of blood (2000 rpm, 10 
min and 4°C). The supernatant was filled in 5 ml aliquots. For short-term storage, the 
aliquots were kept at 4°C, for long-term storage, aliquots were kept at -20°C. Preimmune 
sera (PS) were generated from blood samples before an immunization while immune sera 
(IS) were generated after a specific time depicted in Table 17. The period between the first 
immunization and the taking of blood is 60, 91, 107 or 115 days in order to allow the animal 
for an appropriate immune response. 
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Table 17: Overview of preimmune and immune sera. 
ANTIGEN/ANIMAL DAY PS/IS 
Anna 19.01.2007 PS 
yH2AX-KLH (Anna) 27.03.2007 IS 
Annabel 12.05.2009 PS 
ß-Catenin-GST 21.07.2009 IS 
Sina 03.11.2009 PS 
hDnmt1 02.02.2010 IS 
For the serum ELISA, 1 µg of the appropriate antigen was coated in a 96 well plate 
(Maxisorp, Thermo Scientific) and the serum (PS or IS) was added in serial dilutions. Bound 
alpaca antibodies were detected with an HRP-conjugated anti-Llama IgG antibody (Bethyl 
Laboratories). By adding substrate solution containing the chromogenic substrate 3,3’,5,5’-
Tetramethylbenzidin (TMB) a conversion reaction catalyzed by the HRP takes place resulting 
in a blue coloring of the solution. The reaction was stopped by adding sulfuric acid resulting 
in a yellow coloring which was measured in a microplate reader (Infinite M1000, Tecan; 
absorbance 450 nm). 
2.2.4.3 Isolation of B cells 
The isolation of B cells was performed by Ficoll-gradient. During the first experiments, 
UNI-SEPMAXI (NOVAmed) was used yielding ~ 5 x 10
6 B cells. To further enhance the B cell 
yield, Lymphocyte Separation Medium LSM 1077 (PAA) was tested resulting in ~ 1 x 108 B 
cells. Even though both separation methods are based on Ficoll, higher numbers of B cells 
were obtained by applying the LSM 1077. The isolation was carried out according to the 
respective manufacturer´s instructions. The cell number was determined by counting in a 
Neubauer counting chamber. 
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2.2.5  Phage Display Technology 
2.2.5.1 Construction of a VHH library 
2.2.5.1.1 RNA extraction from B cells 
To prepare total RNA from B cells during the first experiments, 1 x 106 B cells were used 
and RNA was extracted with TRIzol reagent (Life Technologies) according to the 
manufacturer´s protocol resulting in RNA yields between 0,6 – 0,9 µg. To maximize the RNA 
yield and hence enabling the generation of a maximum sized library, Nucleospin RNA XS Kit 
(Macherey-Nagel) was used according to the manufacturer´s protocol during later 
experiments resulting in higher RNA yields between 0,75 – 4,2 µg. To further enlarge the 
RNA yield, during the latest experiments also the number of B cells was increased: 2 x 107 B 
cells were used for RNA preparation resulting in equal RNA yields of up to 11,2 – 17,6 µg. 
The concentration of the RNA was measured spectrophotometric (NanoVue Plus, GE 
Healthcare; absorbance 260 nm). 
2.2.5.1.2 RNA-agarose gel electrophoresis 
Gelectrophoretical analysis of RNA were performed with agarose gels used for DNA-
agarose gel electrophoresis (1% (w/v), 0,025 µg/ml ethidium bromide, 1x Tris-Acetate-EDTA 
(TAE) buffer).  
2.2.5.1.3 cDNA synthesis 
Complementary DNA (cDNA) was amplified using the First-Strand cDNA Synthesis Kit 
from GE Healthcare according to the manufacturer´s protocol. 
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2.2.5.1.4 Amplification of VHH repertoire 
Polymerase chain reaction (PCR) was used to amplify the VHH repertoire and to introduce 
restriction sites via primers for a subsequent cloning step. The amplification of VHHs is 
performed by 3 subsequent nested PCR reactions using 6 different VHH-specific primers. As 
DNA template for the first PCR (PCR1, see Table 18) cDNA from isolated B cells was used. The 
amplification product of the first PCR was loaded on an agarose gel (as described in 2.2.1.8), 
purified and eluted (as described in 2.2.1.9) and was used as template for the second PCR 
(PCR2, see Table 19). The amplification product of the second PCR was prepared accordingly 
and was used as template for the third PCR (PCR3, see Table 20). For all three PCRs one PCR 
program was used (see Table 21). 
Table 18: Preparation scheme PCR1. 
COMPONENT AMOUNT FINAL CONCENTRATION 
Template DNA (cDNA) 3 µl  
Call001 (c= 10 pmol/µl) 0,5 µl 0,2 µM 
Call002 (c= 10 pmol/µl) 0,5 µl 0,2 µM 
5x Phusion buffer 5 µl 1x 
dNTP Mix (c= 
10mM/nucleotide) 
0,5 µl 200 µM/nucleotide 
Phusion Polymerase 0,5 µl 0,08 U/µl 
ddH2O 15 µl  
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Table 19: Preparation scheme PCR2. 
COMPONENT AMOUNT FINAL CONCENTRATION 
Template DNA (PCR1) 1 µl  
Call002 (c= 10 pmol/µl) 0,5 µl 0,2 µM 
SM017 (c= 10 pmol/µl) 0,25 µl 0,1 µM 
SM018 (c= 10 pmol/µl) 0,25 µl 0,1 µM 
5x Phusion buffer 5 µl 1x 
dNTP Mix (c= 
10mM/nucleotide) 
0,5 µl 200 µM/nucleotide 
Phusion Polymerase 0,5 µl 0,08 U/µl 
ddH2O 17 µl  
Table 20: Preparation scheme PCR3. 
COMPONENT AMOUNT FINAL CONCENTRATION 
Template DNA (PCR2) 1 µl  
A4 short (c= 10 pmol/µl) 1 µl 0,2 µM 
38 reverse (c= 10 pmol/µl) 1 µl 0,2 µM 
5x Phusion buffer 10 µl 1x 
dNTP Mix (c= 
10mM/nucleotide) 
1 µl 200 µM/nucleotide 
Phusion Polymerase 1 µl 0,08 U/µl 
ddH2O 35 µl  
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Table 21: PCR program used for the amplification of the VHH repertoire. 
STEP TEMPERATURE TIME NUMBER OF CYLCES 
Initial denaturing 94°C 3 min 1 
Denaturing 94°C 15 s  
Annealing 55°C 15 s 35 
Extension 72°C 30 s  
Final extension 72°C 8 min 1 
 4°C ∞  
The amplification product of PCR3 was prepared accordingly followed by a restriction 
digestion with the endonucleases NcoI and NotI (see Table 22). In parallel the plasmid vector 
pHEN4 was also treated with the endonucleases (see Table 23) producing compatible 
overhangs in order to ligate them according to 2.2.1.10 in up to 30 ligation preparations. The 
ligations were dialyzed against ddH2O. 
Table 22: Restriction digest of PCR3. 
COMPONENT AMOUNT 
DNA PCR3 30 µl 
NotI 1 µl 
NcoI 1 µl 
Buffer 5 µl 
ddH2O 13 µl 
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Table 23: Restriction digest of pHEN4. 
COMPONENT AMOUNT 
pHEN4 10 µg 
NotI 0,5 µl 
NcoI 0,5 µl 
Buffer 1 µl 
ddH2O ad 10 µl 
2.2.5.1.5 Transformation of TG1 cells and library generation 
Electro-competent TG1 cells (Agilent) were used to generate VHH-libraries. They were 
transformed by electroporation with the ligation preparations according to the 
manufacturer´s protocol. For each library up to 30 transformations were performed. The 
transformed bacteria were plated on 2xYT plates containing 100 µg/ml ampicillin and 2% 
(w/v) glucose (2xYTamp/glu plates) and incubated overnight. From these plates single clones 
were picked randomly in order to determine the diversity of the library by sequencing 
analysis (2.2.1.11). In addition the library size was determined by counting the single clones 
on each plate. 
The plates were floated off with 10 ml 2xYT medium containing 100 µg/ml ampicillin and 
2% (w/v) glucose (2xYTamp/glu medium) and glycerol stocks were prepared of each library 
according to 2.2.1.2 resulting in the primary phage display libraries. 
2.2.5.2 Cultivation and preparation of phage particles 
To produce phage particles presenting the VHH library on their tips, TG1 cells containing 
the VHH library were inoculated in 2xYTamp/glu medium and infected with the hyperphage 
(Progen) within their logarithmic growth phase. After an incubation time of 30 min the 
culture was harvested by centrifugation and the pellet was resuspended in 2xYT medium 
containing 100 µg/ml ampicillin and 25 µg/ml kanamycin (2xYTamp/kana medium) and 
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incubated shaking over night at 37°C. The next day the recombinant VHH-containing phages 
are found in the supernatant which was purified by centrifugation. After an incubation with 
20% polyethylene glycol 6000 (PEG 6000) for 1 h on ice, the phage particles were 
precipitated by centrifugation (30 min, 4000 rpm, 4°C). The pellet was resuspended in 1x PBS 
and represents the VHH-library which can be used for panning. 
2.2.5.3 Determination of library sizes 
To assess library sizes, the phage titer was determined by counting colony forming units 
(cfu) of TG1 cells which were infected with phage particles and plated on selectionagar. It is 
assumed that each phage particle infects one bacterial cell which thereby acquires an 
ampicillin resistance resulting in one bacterial colony once this bacterial cell is plated on agar 
including ampicillin. 
2.2.5.4 Solid phase panning 
Solid phase panning is a conventional, widely used method to select antibodies or 
antibody fragments. To perform the panning, 10 µg antigen were coated in immunotubes 
(Thermo Scientific) overnight at 4°C. In order to block the free binding capacity of the 
polystyrol wall, 4% skimmed milk powder in PBS (MPBS) or (in later experiments) Pierce 
protein free blocking buffer (PFBB) (Thermo Scientific) was added.  
Before the first panning round a so called absorption panning was performed. The phage 
particles (generated as described in 2.2.5.2) were added to an immunotube which was not 
coated with antigen but blocked with MPBS or protein free blocking buffer (PFBB) in order to 
eliminate VHH-phage particles unspecifically binding to components of milk/ the blocking 
solution. The phages in the supernatant were then used for solid phase panning and added 
to the immunotube coated with the appropriate antigen and incubated 90 min at room 
temperature. In parallel a negative control was performed with no antigen coated in the 
immunotube. After 10 to 30 washing steps (number of washings steps increases with each 
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panning round) with PBS/Tween20 0,05% the phages were eluted with 0,1 M HCl and 
neutralized with bicarbonate buffer (1M Tris/Cl, pH 9,0) or 100 mM triethylamine (TEA) 
solution, pH 12 an neutralized with 1M Tris, pH 7,4-8. The eluted phage particles were used 
for reinfection of TG1 cells which were then used for the subsequent panning round. 
2.2.5.5 Native panning 
Native panning varies from solid phase panning in terms of the presentation of the 
antigen. In solid phase panning recombinant antigen is directly coated to the surface of 
immunotubes. In native panning cell lysate from HEK293T cells expressing the antigen in 
fusion with GFP (prepared as described in 2.2.3.8) was prepared, immunoprecipitated using 
the GFP-multiTrap (ChromoTek GmbH) (Pichler et al., 2012) and used as antigen for phage 
display. 
Phage particles presenting VHHs on their tips were prepared as described in 2.2.5.2. In 
order to decrease VHHs unspecifically binding to GFP, lysate of HEK293T cells expressing GFP 
only was immunprecipiated in the GFP-multiTrap and used as antigen. Phages were added 
and incubated. The unbound phages were added to the immunoprecipiated antigen-GFP-
fusion protein. After an incubation time of 2 h at room temperature 10-20 washing steps 
were performed with PBST and 1 washing step with PBS. Bound phages were eluted as 
described in 2.2.5.4 and used for reinfection. 
2.2.5.6 Phage ELISA 
Phage ELISA was used to select phage clones presenting antigen specific VHHs on their tips. 
To this end phage particles were cultivated and prepared as described in 2.2.5.2 in 96-well 
assay blocks (Schubert & Weiss). Antigens were coated (1 µg/well) in 96-well MaxiSorp 
mictrotiter plates (Thermo Scientific) and blocked with MPBS or PFBB as described in 2.2.5.4. 
Phage particles were added and incubated for 2 h at room temperature. After 3 washing 
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steps with PBST (0,05% Tween20) and 3 washings steps with PBS bound phages were 
detected with an anti M13-HRP antibody (GE Healthcare) as described in 2.2.4.2.
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3 Results 
The multitude of established as well as unique applications of VHHs, ranging from 
classical biochemical methods (as Nanotraps) over cell biological techniques (in 
immunofluorescence) to live cell detection of endogenous proteins (as Chromobodies) 
elucidates the complexity of their functional requirements. In order to meet the necessary 
specifications the whole upstream screening and identification process has to be adjusted. 
The main objective of this thesis was to develop a robust and reliable process essential in 
the course of the generation of antigen specific VHHs for intended downstream applications. 
This comprises the selection of the antigen, design of the corresponding phage display 
library and an efficient selection process (see Figure 11). Furthermore, during this thesis 
antigen specific VHHs were functionally characterized in different approaches for their 
applicability as Nanotraps and Chromobodies. 
 
Figure 11: Schematic overview of the generation process of antigen specific VHHs (Zolghadr, 2007). 
The results are divided in two sections. The first section depicts strategies to generate 
and identify antigen specific VHHs. As the very first step to generate antigen specific binding 
molecules, alpacas were immunized with a set of different antigens. 
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Subsequently, the VHH repertoire was cloned into a phagemid vector resulting in a 
comprehensive phage display library. To screen for antigen specific VHHs phage display with 
several rounds of panning was performed, resulting in the selection of antigen specific VHHs. 
According to the downstream application the method phage display was modified. First, 
solid phase panning with recombinant proteins was used to select for antigen specific VHHs. 
Next, a native panning strategy was developed. For this purpose, antigen was expressed in 
mammalian cells to promote the selection of VHHs recognizing the native confirmation of the 
antigen. Antigen specific clones were identified either by phage ELISA or by combining the 
phage display with the cell based fluorescent-2 hybrid (F2H) screening assay.  
In the second section, antigen specific VHHs were characterized according to the 
intended application by two different approaches: biochemical functionality and 
intracellular, in vivo functionality. To further understand the mode of binding, the epitopes 
of the VHHs were mapped by phage ELISA and Dot Blot analysis. In order to test the 
functionality of the antigen specific VHHs and their suitability as Nanotraps biochemical 
assays like immunoprecipitations and pulldown assays were performed. In addition, to test 
their capacity to recognize (partially) denatured antigens, they were analyzed in 
immunofluorescence experiments. An important aspect is the intracellular functionality of 
the VHHs fused to fluorescent fusion proteins – so called Chromobodies, hence they were 
analyzed regarding their functionality in live cell imaging in mammalian cells. 
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3.1 Generation and selection of antigen specific VHHs 
3.1.1 Antigen selection 
One of the most crucial steps in generating antigen specific VHHs is the immune response 
following immunization. Hence, one goal of this thesis was to analyze immune response in 
regard to antigen characteristics. Therefore, five different kinds of antigens ranging from 
peptides to complex proteins were immunized (see Table 24). 
Table 24: Overview of applied antigens. 
APPLIED ANTIGEN CHARACTERISITCS 
yH2AX-KLH Peptide coupled to KLH 
HIV-1 CA Middle-sized, viral protein (24 kDa) 
PCNA Middle-sized protein (28 kDa) 
ß-Catenin-GST Fusion-protein (118 kDa) 
hDnmt1 Large protein (150 kDa) 
1) Histone H2AX is a protein associated with the DNA and involved in DNA-repair. After 
a DNA-doublestrand break occurs, H2AX gets phosphorylated at serine 139. The 
phosphorylated version is referred to as yH2AX (Rogakou et al., 1998). During this 
thesis the peptide KATQAS (amino acid residues 134-139) was immunized coupled to 
the carrier KLH (Keyhole Limpet Hemocyanin found in arthropods and mollusca) in 
order to enhance the immune response to the non-immunogenic peptide. 
2) The HIV-1 capsid protein (HIV-1 CA) is an internal capsid domain of the HIV-1 GAG 
polyprotein which orchestrates viron assembly of HIV-1 (Helma et al., 2012). For 
immunization recombinant HIV-1 CA was produced in E. coli and purified via a C-
terminal his6-tag (kindly provided by H. G. Kräußlich, Universitätsklinikum Heidelberg, 
Germany). 
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3) The proliferation cell nuclear antigen (PCNA) is involved in DNA-replication and forms 
a homotrimer. It comprises the central loading platform for enzymes involved in DNA 
replication (Moldovan et al., 2007). Like HIV-1 CA, for immunization recombinant 
PCNA was produced in E. coli and purified via a C-terminal his6-tag (kindly provided 
by M. C. Cardoso, MDC Berlin, Germany). 
4) ß-Catenin is the key mediator of the wnt-pathway. Within cells, ß-Catenin is localized 
at the plasma membrane where it is involved in the formation of cell-cell contacts. 
Beside the membrane bound fraction a soluble pool fraction of ß-Catenin exists in 
the cytoplasm and the nucleus. After induction of the wnt-pathway ß-Catenin is 
translocated into the nucleus and acts as transcriptional coactivator (Valenta et al., 
2012). Immunization was performed using a N-terminally Glutathione S transferase 
(GST) version of human ß- Catenin (kindly provided by O. Poetz, NMI Reutlingen, 
Germany). Glutathione S-transferase (GST) is a 26 kDa protein used to purify proteins 
(Terpe, 2003). 
5) The large human protein DNA (cytosine-5)-methyltransferase 1 (hDnmt1) is an 
epigenetic marker and maintains DNA methylation patterns during DNA-replication 
(Goll and Bestor, 2005). As the recombinant production of Dnmt1 in E. coli was only 
minor efficient, Dnmt1 was produced using a baculovirus system and purified via a C-
terminal his6-tag (kindly provided by C. Frauer, LMU Munich, Germany). 
During the immunization period each alpaca received intramuscular injections at weekly 
intervals (kindly conducted by S. Nüsske, LMU Munich, Germany). On bleeding day, 100 – 
150 ml blood was collected from each alpaca. To monitor the humoral immune response of 
the alpacas a solid-phase ELISA on immobilized antigen using serum samples from day 0 (pre 
immunization) and post immunization was performed exemplary for yH2AX, hDnmt1 and ß-
Catenin-GST. Bound alpaca antibodies were detected by an anti-lama IgG antibody which 
specifically recognizes the Fc part of the alpaca antibodies. The results of these experiments 
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show strong reactivity of the serum post immunization, but not pre immunization. Figure 12 
shows the serum test for alpaca Sina before (Figure 12 A) and after the immunization (Figure 
12 B) with hDnmt1 and for alpaca Annabel after the immunization with GST-ß-Catenin 
(Figure 12 C). The post immunization test for yH2AX did not show increased reactivity (data 
not shown). 
 
Figure 12: Immune response in alpaca. Alpaca Sina was immunized with recombinant hDnmt1, alpaca 
Annabel was immunized with GST-ß-Catenin. Blood samples from Sina were taken at day 0 and 91 post 
immunization and the serum anti-hDnmt1 response was evaluated in solid phase ELISA. Blood samples from 
Annabel were taken at day 103 post immunization and the serum anti-GST response was evaluated in solid 
phase ELISA. (A) Preimmune serum anti-hDnmt1 response on recombinant hDnmt1 (NK: Ubiquitin). (B) 
Postimmune serum anti-hDnmt1 response on hDnmt1 (NK: VSVG). (C) Postimmune serum anti-GST response 
on GST (NK: GFP). 
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3.1.2 Amplification of the VHH repertoire 
Following the test, that the alpaca generated antibodies against the specific antigen in 
general, the VHH repertoire of the immunized animal was amplified to create a 
comprehensive VHH phage display library. 
3.1.2.1 RNA extraction and cDNA synthesis 
To select antigen specific VHHs from a VHH library via phage display, the library size and 
diversity is of vital importance. B cells from immunized alpacas were used as basis to 
generate a comprehensive VHH library since they should preferentially contain mRNA 
encoding for antigen specific VHHs. One important step to ensure a large and diverse library 
is to maximize the mRNA yield. 
First, the preparation of a maximum number of intact B cells from peripheral blood is 
required. In brief, 100 – 150 ml heparinized blood from immunized alpacas was added to 
Ficoll density gradient media filled tubes and the separation process of B cells from other 
blood components was performed by centrifugation. As described in the materials and 
methods section, different strategies were tested in order to enhance the yield of B cells, 
finally resulting in ~ 1 x 108 B cells. Subsequently, total RNA was extracted from the prepared 
B cells. Again, different methods as described in the material and methods section were 
tested and optimizedin order to enhance the RNA yield, finally resulting in 11,2 – 17,6 µg 
RNA per 1 x 108 B cells. The extracted RNA was used as template for cDNA synthesis using 
oligo dT primers. 
3.1.2.2 PCR amplification 
The next crucial steps in library generation are the polymerase chain reactions (PCR 
reactions) performed to amplify the VHH repertoire. Several different variations regarding 
the number of PCR cycles, the primer composition and the number of PCRs were performed. 
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The highest diversity was achieved by 3 subsequent nested PCR reactions employing 6 
different primers as depicted in Figure 13. 
 
Figure 13: Schematic overview of the three subsequent polymerase chain reactions (PCRs) with the most 
important restriction sites plotted. 
CDNA from total RNA was used as template to amplify genes encoding the variable 
domains of the heavy chain antibodies. After the first PCR two specific products are obtained 
(see Figure 14 A) allowing for the discrimination between VH and VHH repertoire. The first 
product with a size of ~ 1 kb encoding the variable regions VH, the CH1, the hinge and parts of 
the CH2 exons of the heavy chain of conventional antibodies. The second PCR product runs at 
~ 0,7 kb and encodes the variable regions VHH, hinge and part of the CH2 exons of the heavy 
chain antibodies (see Figure 14 A). The PCR product at ~ 0,7 kb was used as template in the 
next PCR step. In a second, nested PCR the restriction site NcoI is introduced. The PCR 
product ranging from FR1 to CH2 is ~ 0,7 kb in size (see Figure 14 B) was used as template in 
the last PCR step. Within the third PCR three more restriction sites (SfiI, NotI) necessary for 
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subsequent cloning steps are introduced. The primer anneal in FR1 and FR4 resulting in 
amplification of VHHs with ~ 0,4 kb in size (see Figure 14 C). 
 
Figure 14: Exemplary overview of PCRs. (A) In a first PCR reaction the specific primers CALL001 and 
CALL002 amplify the repertoire of VHHs (~ 0,7 kb) and VHs (~ 1 kb). Lane 1: MW marker, Lane 2: PCR. The whole 
PCR reaction sample was separated on a 1 % agarose gel for 40 min at 100 V. (B)  In a second PCR reaction the 
specific primers SM017/018 and CALL002 specifically amplify the repertoire of VHHs and the restriction site 
NcoI is introduced. Lane 1: MW marker, Lane 2: PCR. The whole PCR sample was separated on a 1 % agarose 
gel for 40 min at 100 V. (C) In a third nested PCR reaction the specific primers A4 short and 38 introduce the 
restriction sites SfiI, NotI. Lane 1: MW marker, Lane 2: PCR. 10% PCR sample was separated on a 1 % agarose 
gel for 40 min at 100 V. Shown are representative results of the amplification of VHHs from alpaca Sina. 
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3.1.3 Cloning of VHH library in pHEN4 
In order to obtain a highly diverse and large VHH phage display library the ligation step of 
the VHH repertoire and the corresponding phagemid vector pHEN4 and the subsequent 
transformation are the next important steps. In order to do so, the VHH repertoire was 
ligated after amplification into the phagemid vector pHEN4 upstream and in frame with the 
capsid protein gene gIII using the restriction sites NcoI and NotI and transformed by 
electroporation into E. coli TG1 cells resulting in a phage display library, called primary 
library (see Figure 15).  
 
Figure 15: Digest of PCR3 and pHEN4 with NcoI and NotI. Lane 1: digested PCR3, Lane 2: MW marker, Lane 
3: digested pHEN4. Samples were seperated on a 1 % agarose gel for 40 min at 100 V. Shown are 
representative results of the amplification of VHHs from alpaca Sina. 
To maximize the VHH library sizes, not only the absolute amount of DNA ligated but also 
the number of successful transformations is crucial. Initially, 4 - 6 ligation preparations were 
done; later up to 30 ligations were prepared. The number of transformations was increased 
from 3 x 40 µl during the first experiments to 30 x 40 µl during the latest experiments. 
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Another important factor influencing library size is transformation efficiency displayed by 
the discharge time constant during electroporation which should be close to 5 ms and is 
decreased in the presence of salt. In addition, the presence of salt may cause short-circuits 
during electroporation which destroy the transformation preparation. Hence, to prepare salt 
free DNA the ligations were purified by phenol/chloroform extraction and ethanol 
precipitation during the first experiments. The electroporations showed time constants of 
3,7 - 4,1 ms. Later, the protocol was further modified and ligations were dialyzed achieving 
higher time constants of up to 4,9 ms resulting in increased transformation efficiency. 
To determine the size of the primary libraries, TG1 cells when transformed with the 
primary phage library were plated in serial dilutions and colony forming units (cfu) were 
counted. The library sizes for the different antigens are depicted in Table 25. 
Table 25: Sizes of primary libraries. 
APPLIED ANTIGEN LIBRARY SIZE 
yH2AX-KLH 6 x 103 clones 
HIV-1 CA 1,1 x 104 clones 
PCNA 8,1 x 10³ clones 
GST-ß-Catenin 6,2 x 105 clones 
hDnmt1 1,5 x 105 clones 
To verify the quality of the library regarding the insertion of the VHH in the pHEN4, DNA 
of randomly picked colonies was digested with restrictions enzymes NcoI and BstEII. The 
results show that 70 % to 80 % of the transformants had an insert of proper size with ~ 0,4 
kb. The slightly different sizes of the VHH fragments indicate the diversity of the VHH primary 
library (see Figure 16). 
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Figure 16: Restriction analysis of VHH primary library. Lane 1 – 10 : Exemplary the digest of DNA of 
randomly picked clones from the Sina-VHH primary library with NcoI and BstEII is shown. Lane 11: MW marker. 
Samples were separated on a 1 % agarose gel for 40 min at 100 V. 
The cloning of the PCR product with the corresponding restriction enzymes results in an 
open reading frame of the pHEN4 phagemid adding an N-terminal pelB leader sequence to 
the putative VHH domain which facilitates the transport of the expressed protein to the 
bacterial periplasm to ensure the correct formation of the essential disulfide bonds. In 
parallel a C-terminal gIII fusion is generated. Between VHH and gIII an amber stop codon is 
located (see Figure 17). Stop codons generally signal the termination of translation. 
However, depending on the bacterial strain, the amber stop codon is read by a 
corresponding tRNA allowing the translation of the stop codon in the amino acid glutamine 
and hence the production of a full-length fusion protein. For this to occur, the primary 
library is transformed into the suppressor strain TG1 and the amber stop codon gets 
translated, resulting in the expression of the surface fusion protein VHH-pIII for further 
analysis in phage display.  
 
Figure 17: Schematic of VHH gene locus in pHEN4. 
To further analyze the diversity of the libraries, at least ten randomly picked single clones 
from each library were sequenced. Four out of five libraries were found to be highly diverse 
(see Figure 18 and Figure 19). Within these four primary libraries (HIV-1_primary, ß-Catenin-
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GST_primary, PCNA_primary and Dnmt1_primary) all sequences were unique. Within the 
primary library of γH2AX one of the sequences appears three times, another sequence 
appears twice. The CDR3s show differences in length between four (Dnmt1_primary#1) and 
26 (γH2AX _primary#1) amino acid residues. In the FR2 region, the characteristic hydrophilic 
amino acid substitutions at positions 37, 44, 45, 47 can be found, except for some sequences 
showing the hydrophobic residues of classical VHs, e.g ß-Catenin-GST_primary#5. 
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Figure 18: Sequence alignment of VHH amino acid sequences of primary libraries: (A) HIV-1, (B) γH2AX, (C) ß-Catenin-GST. Color code (used throughout): CDR1: red, 
CDR2: blue, CDR3: green, hallmark residues: violet. Numbering after Kabat et al. (Kabat, 1991). 
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Figure 19: Sequence alignment of VHH amino acid sequences of primary libraries: (A) PCNA, (B) hDnmt1. Color code: CDR1: red, CDR2: blue, CDR3: green, hallmark 
residues: violet. Numbering after Kabat et al. (Kabat, 1991).  
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3.1.4 Phage Display 
To select antigen specific VHHs the phage display method was applied. Even though this 
method is widely used to select antibody fragments, it requires experience, effort and 
optimization to robustly select functional antigen specific molecules. Initially, classical solid 
phase panning with immobilized antigens was performed (Bradbury and Marks, 2004). For 
solid phase panning recombinant antigen was produced in E. coli, insect cells or synthetically 
manufactured. In the progress of this work, this protocol was adapted and optimized 
according to the proposed downstream application of the selected VHHs and a unique 
panning strategy was developed, the so called native panning. Here, antigen expressed in 
mammalian cells is used for panning selecting for VHHs which recognize the native folded 
antigen.  
3.1.4.1 Solid Phase Panning 
To isolate antigen specific VHHs the primary libraries were used in recursive rounds of 
selection on the appropriate antigen (see Table 26).  
Table 26: Antigens used in phage display. 
SCREENED ANTIGEN CHARACTERISTICS 
yH2AX-BSA Peptide coupled to BSA (synthetically manufactured) 
HIV-1 CA Fullength viral protein (24 kDa; produced in E. coli) 
HIV-1 CA N-terminal domain Domain of viral protein (15 kDa; produced in E. coli) 
PCNA Middle-sized protein (28 kDa; produced in E. coli) 
GST Protein tag (26 kDa; produced in E. coli) 
hDnmt1 Large protein (150 kDa; produced in insect cells) 
The antigens were immobilized in plastic immunotubes and phages presenting VHHs on 
their tips were added. After a defined number of washing steps with increased stringency 
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the phages were eluted and used for re-infection of TG1 cells in preparation for the next 
round of panning. 
Even though there are many protocols available to select antibody fragments using solid 
phase panning, during the work for this thesis a number of optimizations were necessary to 
secure the selection of antigen specific VHHs. In order to obtain antigen specific VHHs only, 
the selection and enrichment of nonspecific phages needs to be avoided. Since filamentous 
phages, like M13, have been shown to bind nonspecifically to support surfaces like 
immunotubes (Bradbury and Marks, 2004) blocking is vital. Therefore, different blocking 
methods were tested. Traditionally, 4 % skimmed milk powder in PBS is used for blocking. 
However, we found out that phages strongly bind components of milk (data not shown). 
Consequently, to reduce unspecific binding of the phages to components of milk, protein 
free blocking solution (Pierce Biotechnology Inc.) was used, resulting in decreased unspecific 
binding (data not shown). To further eliminate phages which still bind to the immunotube 
surface, the eluted phages were added to blocked immunotubes without coated antigen 
after the first panning round. The unbound phages were used for re-infection of TG1 cells 
representing antigen specific phages. 
The next critical step is the elution of bound VHHs from the antigen. On the one hand, it 
is crucial to elute all bound phages to obtain the full repertoire of antigen specific VHHs. On 
the other hand, the elution method needs to be as gentle as possible to make sure the VHHs 
are not damaged resulting in non-functional VHHs. In general, phages presenting antibody 
fragments on their tips can be eluted from the antigen in a number of different ways ranging 
from acidic (Roberts et al., 1992) to basic solutions (Marks et al., 1991) or proteolytic 
cleavage (Ward et al., 1996). Here, two different approaches were tested: acidic elution with 
0,1 M HCl and basic elution with 0,1 M triethylamine showing the latter being the more 
suitable elution method resulting in more functional phages (data not shown). 
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In general, at least three panning rounds were performed, except for GST and HIV-1 CA 
N-terminus, where fewer rounds were sufficient to generate potent antigen specific VHHs 
(one panning round and two panning rounds, respectively). For each panning round the 
respective antigen is coated in an immunotube. In addition, a negative control without 
coated antigen is preformed in parallel in order to evaluate the number of phages binding 
unspecifically to the surface of the immunotubes or components of the blocking solution. In 
each subsequent panning round, the number of washing steps was increased to enhance 
stringency. Before and after each round of panning the library size was evaluated by 
counting the colony forming units (phage titer) of TG1 cells infected with phage particles (as 
described in 2.2.5.3). Figure 20 and Figure 21 show the library sizes before and after each 
performed panning. The phage titer usually increases between panning rounds indicating 
that selection is occurring, as shown in Figure 20 B, Figure 20 B and Figure 21 C.  
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Figure 20: Overview of library sizes of HIV-1 capsid pannings. (A) The number of colony forming units for 3 
panning rounds against the fulllength HIV-1 CA, HIV-1 CA 1p, HIV-1 CA 2p and HIV-1 CA 3p, is depicted. The 
numbers show, that there is no significant change of phage titer over the three panning rounds. (B) The 
number of colony forming units for 2 panning rounds against the N-terminus of the HIV-1 CA, HIV-1 CA N-term 
1p and HIV-1 CA N-term 2p, is depicted. The results show, that the number of colony forming units increases 
from panning to panning. 
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Figure 21: Overview of library sizes pannings against PCNA, yH2AX, hDnmt1, GST. (A) The number of 
colony forming units for 3 panning rounds against PCNA, PCNA 1p, PCNA 2p and PCNA 3p, is depicted. The 
numbers show, that there is no significant change of phage titer over the three panning rounds. (B) The 
number of colony forming units for 4 panning rounds against γH2AX, γH2AX 1p, γH2AX 2p, γH2AX 3p and 
γH2AX 4p, is depicted. The numbers of colony forming units after the first panning round and the 
corresponding negative control are almost identical hinting that no selection occurs. In subsequent panning 
rounds the phage titer increases panning by panning. (C) The number of colony forming units for 3 panning 
rounds against hDnmt1, hDnmt1 1p, hDnmt1 2p and hDnmt1 3p, is depicted. The numbers of colony forming 
units after the first panning round and the corresponding negative control are almost identical hinting that no 
selection occurs. In the 2 subsequent panning rounds the numbers show, that there is significant change of 
phage titer from panning to panning. (D) The number of colony forming units for 1 panning round against GST, 
GST 1p, is depicted. 
 
 
3 Results 
 
86 
 
3.1.4.2 Native Panning 
As described in 1.2.2.1, solid phase panning may have several drawbacks regarding the 
presentation of the antigen. In order to select antigen specific VHHs recognizing epitopes of 
native proteins for in vivo applications the presentation of the antigen is crucial. Several 
methods are known employing antigen specific antibodies or biotinylated antigen captured 
by streptavidin beads (Hawkins et al., 1992). As described in 3.1.4.1 filamentous phages have 
strong tendency to bind unspecifically to a variety of structures. Therefore, the application of 
biotinylated antigen has high potential to raise biotin but not antigen specific VHHs. To 
circumvent these problems, the native panning method was developed during this thesis 
with hDnmt1 as proof of principle (Figure 22). 
In brief, in a first step hDnmt1 was genetically fused to the green fluorescent protein 
(GFP). GFP alone and the fusion protein GFP-hDnmt1 were expressed in mammalian cells 
and cell lysate was produced. For the panning GFP and the GFP-hDnmt1 was purified using a 
96-well microplate comprising an immobilized GFP-binding protein (GFP-Trap) (Figure 22 (1)) 
(Pichler et al., 2012). Phage particles derived from the hDnmt1 primary library presenting 
VHHs on their tips were produced. To avoid the enrichment of GFP specific VHHs the phages 
were added to the immobilized GFP, followed by a defined number of washing steps (Figure 
22 (2)). Half of the unbound phages were added to the immobilized GFP-hDnmt1 to select 
for hDnmt1 specific VHHs (Figure 22 (3) and (4)). In parallel, the other half of the unbound 
phages were added to a well with no antigen immobilizes in order to assess the number of 
phage unspecifically binding to the surface of the microplate. After a defined number of 
washing steps, the phages were eluted and used for re-infection of TG1 in preparation of a 
subsequent panning round. Figure 23 shows the results of solid phase and native panning 
against hDnmt1. After the first panning round, there is no unspecific background using 
native panning and the library size is 10 times bigger than after solid phase panning. After 
the second panning, however, there is unspecific background with both panning methods 
and the library after solid phase panning is 10 times bigger than after native panning. 
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Figure 22: Schematic outline of the native panning strategy to enrich phages displaying VHHs specific for 
hDnmt1. (1) Cell lysate expressing GFP and GFP-hDnmt1 was added to a 96-well microplate with immobilized 
GFP-Trap resulting in the immobilization of GFP and GFP-hDnmt1, respectively. (2) Phage particles presenting 
VHHs from the primary hDnmt1-library on their tips were added to the immobilized GFP in order to eliminate 
VHHs unspecifically binding to the surface of the microplate, the GFP-Trap or GFP. (3) Unbound phages were 
added to the immobilized GFP-hDnmt1. (4) Unbound phages were washed away and bound phages were 
eluted. 
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Figure 23: Overview of library sizes of solid phase panning and native panning against hDnmt1. (A) The 
number of colony forming units for 2 panning rounds against hDnmt1, hDnmt1 1p and hDnmt1 2p, is depicted. 
The numbers show, that there is significant change of phage titer from panning to panning. A negative control 
(NK) was performed in parallel with blocked immunotubes. (B) The number of colony forming units for 2 native 
panning rounds against hDnmt1, hDnmt1 1p and hDnmt1 2p, is depicted. The numbers show, that there is no 
significant change of phage titer. A negative control (NK) was performed in parallel using immobilized GFP-Trap 
without precipitated antigen. 
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3.1.4.3 Sequence analysis after Phage Display 
Several rounds of panning against an antigen lead to enrichment of specific VHHs. To 
analyze the enrichment of antigen specific VHHs on DNA level after each panning round, 4 - 
15 randomly picked single clones were sequenced after the panning rounds (see Figure 24 to 
Figure 28), except for the panning of the ß-Catenin-GST library against GST – here, a phage 
ELISA was performed directly after panning. 
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Figure 24: Sequence alignment of VHH amino acid sequences of single clones from γH2AX libraries after solid phase panning against γH2AX-BSA. (A) 1. panning 
round, (B) 2. panning round, (C) 3. panning round. Color code: CDR1: magenta, CDR2: blue, CDR3: green, hallmark residues: violet, identical sequences are marked with a 
red bar. Numbering after Kabat, 1991. 
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Figure 25: Sequence alignment of VHH amino acid sequences of single clones from HIV-1 libraries after solid phase panning against fullength HIV-1 capsid protein. 
(A) 1. panning round, (B) 3. panning round. Color code: CDR1: magenta, CDR2: blue, CDR3: green, hallmark residues: violet, identical sequences are marked with a red bar. 
Numbering after Kabat, 1991. 
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Figure 26: Sequence alignment of VHH amino acid sequences of single clones from HIV-1 library after solid phase panning against HIV-1 capsid protein N-terminus. 
(A) 2. panning round. Color code: CDR1: magenta, CDR2: blue, CDR3: green, hallmark residues: violet, identical sequences are marked with a red bar. Numbering after 
Kabat, 1991. 
3 Results 
 
93 
 
 
Figure 27: Sequence alignment of VHH amino acid sequences of single clones from PCNA libraries after solid phase panning against PCNA. (A) 1. panning round, (B) 2. 
panning round, (C) 3. panning round. Color code: CDR1: magenta, CDR2: blue, CDR3: green, hallmark residues: violet, identical sequences are marked with a red bar. 
Numbering after Kabat, 1991. 
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Figure 28: Sequence alignment of VHH amino acid sequences of single clones from hDnmt1 libraries after (A) solid phase panning against hDnmt1 and (B) native 
panning round against hDnmt1-GFP. Color code: CDR1: magenta, CDR2: blue, CDR3: green, hallmark residues: violet, identical sequences are marked with a red bar. 
Numbering after Kabat, 1991. 
3 Results 
 
95 
 
The VHH sequence alignments of single clones after the pannings depicted in Figure 24 to 
Figure 28 show the characteristic hydrophilic amino acid substitutions (the so called hallmark 
residues) in the FR2 region at positions 37, 44, 45, 47. However, in addition to antigen 
specific VHHs also conventional VH domains comprising hydrophobic residues at the hallmark 
positions in FR2 were found among the enriched sequences (e.g. γH2AX _1p#4, PCNA_2p#3 
or Dnmt1_N_1p#8). One reason for an enrichment of VH domains could be slight 
contamination with VH encoding DNA during the PCR amplification steps which were 
amplified due to the high sequence homologies between VHHs and VHs and then were 
selected as single domains during phage display. 
To compensate the loss of the variable light chain and to increase the antigen binding sites 
VHHs often have extended CDR3s (Muyldermans et al., 1994). This general rule can be 
confirmed by the sequenced clones (see Figure 29). These extended CDR3s are often found 
in VHH domains which also possess an additional cysteine residue, beside the conserved 
cysteine residues at position 22 and 98 which are responsible for the formation of a disulfide 
bond between FR1 and FR3. Here, 78 % of the VHH sequences comprising a long CDR3 (more 
than 15 amino acid residues) possess at least one additional cysteine residue. 
 
Figure 29: Occurrence of CDR3 lengths of VHH selected after phage display. VHH and VH sequences from 
clones sequenced after the panning rounds (see Figure 24 - Figure 28). Numbering after Kabat, 1991. 
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Independent of the antigen or panning round, a significant number of VHHs comprise up to 
three additional cysteine residues in their CDRs. It has been shown that additional cysteines 
in VHHs can either form a CDR3 intraloop disulfide bond or an interloop cysteine bridge 
connecting CDR3 with CDR1 which stabilizes the VHH (Davies and Riechmann, 1996) or 
enables the formation of alternative antigen binding scaffolds (Conrath et al., 2003). The 
results show, that the VHHs sequenced preferentially possess no or two additional cysteines 
while VHs preferentially possess no additional cysteine in their CDRs (see Table 27). 
Table 27: Frequency of occurrence of clones with or without additional cysteines in their CDRs. The 
dataset contained 27 VH and 53 VHH clones. 
 VH (%) VHH (%) 
No cysteine 96 58 
1 cysteine 4 2 
2 cysteines 0 38 
3 cysteines 0 2 
The sequence analysis of clones panned against γH2AX-BSA (see Figure 24) reveal that 
none of the binding molecules contain an additional cysteine after the first panning round, 
however, the sequence analysis after the third panning shows only one VHH sequence 
comprising two additional cysteine residues located in CDR2 and CDR3. This additional 
disulfide bridge could be important to stabilize the antigen recognition interface consisting 
of the hypervariable region CDR2 and CDR3 of the VHH. Interestingly, all VHH domains 
selected against fullength HIV-1 capsid protein (see Figure 25) do not have additional 
cysteine residues, while the selected VHH sequences against the N-terminal domain of HIV-1 
capsid protein comprise two additional cysteine residues in their CDR3 which is much longer, 
too (see Figure 26). The sequences of clones after pannings against PCNA show a decreasing 
number of cysteine residues after each subsequent panning round (see Figure 27). This could 
be due to the fact that an additional cysteine bridge is not needed to generate a stable 
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folded hypervariable region. None of the VHH sequences of clones panned against hDnmt1 in 
solid phase panning possess an additional cysteine residue, while two clones with two 
additional cysteine residues can be found after native panning (see Figure 28).  
The VHH sequence alignments of single clones after the solid phase pannings against γH2AX-
BSA in Figure 24 reveal an enrichment of one sequence after the first (e.g. γH2AX_1p#5), 
second (e.g. γH2AX_2p#2) and after the third panning round (e.g. γH2AX_3p#2) as well. 
However, the enriched sequences differ after each panning round. Considering the high 
phage titer for the negative control after the first panning round against γH2AX-BSA (Figure 
21) this result indicates an enrichment of unspecific VHHs, e.g. binding to the carrier BSA or a 
component of the blocking solution. 
The VHH sequence alignments of single clones after solid phase pannings against fullength 
HIV-1 capsid protein (Figure 25) show an enrichment of one sequence after the first panning 
(e.g. HIV-1_1p#2). Even though the sequences HIV-1_1p#1 and HIV-1_1p#4 are similar in 
CDR2 and CDR3, they differ in CDR1 in two amino acid residues. This occurrence may be 
explained by the CDR1 of VHHs being a hotspot for somatic hypermutation (Nguyen et al., 
2000). The sequenced clones after the first panning round can be found after the third 
panning round, as well. In addition, a third enriched sequence can be found after the third 
panning round (e.g. HIV-1_3p#3). It is remarkable that all identified VHHs directed against 
the fullength HIV-1 capsid protein have extremely short CDR3s, comprising just four amino 
acid residues. In contrast, the VHH sequences of single clones after the second solid phase 
panning round against the N-terminus of HIV-1 capsid protein (Figure 26) possess long 
CDR3s of 15 amino acid residues including one additional cysteine residue in the CDR3 and in 
the CDR2. Since both pannings were performed using the same phage display library, these 
results can be traced back to the different VHHs being derived from different B-cell pools. 
After the solid phase panning against the N-terminus of HIV-1 capsid protein only one 
sequence was enriched after the second panning round which implies an enrichment of an 
antigen specific VHH. 
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In Figure 27 the VHH sequence alignments of single clones after solid phase panning against 
PCNA are depicted. After the second panning round two sequences are enriched with one 
being a VH (e.g. PCNA_2p#2) and the other one being a VHH (e.g. PCNA_2p#5). The CDR2 and 
CDR3 of the VH PCNA_2p#1, #2, #3 and #12 show a significant homology, but #1 and #3 
differ in the CDR1 in three and one amino acid residues, respectively. This may be explained 
by somatic hypermutation, however, VHs generally have more conserved amino acid 
residues in their CDR1s than VHHs (Muyldermans et al., 2009). After the third panning round 
(see Figure 27 C) only one CDR3 sequence (e.g. as shown in PCNA_3p#15) is strongly 
enriched. However, the clones comprising this particular CDR3 differ in the CDR1 by two (e.g 
PCNA_3p#2) to four (e.g. PCNA_3p#20) amino acid residues, demonstrating that at least two 
different V gene fragments where fused to the same D-J gene fragment. The clones 
sequenced after the panning against PCNA show strong enrichment of VHs after the 
subsequent panning rounds. 
Figure 28 shows the VHH sequence alignments of single clones after the panning against 
hDnmt1 with two different panning approaches being employed: solid phase panning and 
native panning. Figure 28 A shows the alignment of VHH sequences after solid phase panning 
using recombinant hDnmt1 purified from insect cells. Two sequences derived from solid 
phase panning show a high similarity: Dnmt1_SP_1p#2 and Dnmt1_SP_1p#3. However, 
these sequences differ in the CDR3 by two and in CDR2 by one amino acid residue. Figure 28 
B shows the alignment of VHH sequences of single clones after the native panning using 
hDnmt1-GFP from cell lysate. Here, one sequence is enriched (e.g. Dnmt1_N_1p#6). In 
addition, two clones, Dnmt1_N_1p#1 and #2 are similar in CDR2 and CDR3, but they differ in 
CDR1 by two amino acid residues. These minor differences can be explained by the high 
somatic hypermutation rate in VHHs (Nguyen et al., 2000). In contrast to all clones 
sequenced after the solid phase panning this enriched sequence has two additional cysteine 
residues in CDR3. Interestingly, sequences derived from single clones after solid phase 
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panning cannot be found after native panning, indicating that different epitopes are 
recognized with regard to the mode of antigen presentation. 
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3.1.5 Selection of antigen specific VHHS by Phage ELISA 
After several rounds of panning the resulting libraries contain a variety of antigen specific 
VHHs. In order to evaluate the success of the enrichment process and to identify antigen 
specific VHHs for further applications such as Nanotrap or Chromobody, phage ELISA 
(enzyme-linked immunosorbent assay) was performed. The method phage ELISA measures 
the binding of solution-phase phages and is particularly advantageous since it is a simple and 
robust method to confirm the binding specificity of single phage clones. Especially in case of 
poor bacterial expression of the VHH domain, analysis of phages is superior to analysis of VHH 
domains prepared from induced bacterial cultures. Additionally, phage ELISA is 
advantageous because of the signal amplification due to the detection of the coat protein 
pVIII which occurs in multiple copies within the phage surface. In brief, recombinant antigen 
was coated in a microtiter plate. 19 to 48 single phage clones from panned phage libraries 
were added, presenting individual VHHs on their tips. The clones were tested for their 
antigen specificity on the appropriate antigen. In order to verify this result and exclude 
unspecific VHHs, the single clones were tested on a negative control in parallel. 
Although being a very sensitive method, phage ELISA is prone to give false positive 
results and required several optimization steps. First, the unspecific binding of phages to the 
surface of microtiter plates needs to be avoided by using the appropriate blocking solution. 
In the beginning of this thesis 4 % skimmed milk powder in PBS was used. As described in 
3.1.4.1, phages show high unspecific binding to components of milk, hence, protein free 
blocking solution was used later. Second, to ensure a successful selection of antigen specific 
VHHs, efficient coating of the antigen needs to be controlled. Hence, appropriate 
immobilization of an antigen was monitored by using an antigen specific antibody in a 
classical ELISA approach. Last, when working with peptides coupled to carriers like KLH or 
BSA unspecific binding of phages to the carrier protein can occur. To avoid the selection of 
phages binding unspecifically to carriers, the carrier protein was exchanged for the panning 
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and phage ELISA. At the beginning of this work, yH2AX peptide coupled to the carrier KLH 
was used for immunization, phage display and phage ELISA making it impossible to 
distinguish between VHHs specific for the peptide or the carrier protein. Therefore, in later 
experiments, the carrier was changed to BSA in the pannings and the subsequent phage 
ELISAs. 
 
Figure 30: Analysis of HIV-1 capsid specific VHHs by phage ELISAs. The binding of phages presenting 
individual VHHs on their tips was measured at 450 nm. (A) HIV-1 ELISA after third panning round with 
immobilized HIV-1 capsid protein. (B) HIV-1 ELISA after second panning round with immobilized N-terminus of 
HIV-1 capsid protein. NK: negative control. 
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Figure 31: Analysis of GST and yH2AX specific VHHs by phage ELISAs. The binding of phages presenting 
individual VHHs on their tips was measured at 450 nm. (A) GST ELISA after first panning round with immobilized 
GST (B) yH2AX ELISA after third panning round with immobilized yH2AX-BSA. NK: negative control. 
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Figure 32: Analysis of hDnmt1 specific VHHs by phage ELISAs. The binding of phages presenting individual 
VHHs on their tips was measured at 450 nm. (A) Dnmt1 ELISA after first panning round with immobilized 
hDnmt1. (B) Dnmt1 ELISA after second panning round with immobilized hDnmt1. (C) Dnmt1 ELISA of ELISA 
positives from (A) and (B) with immobilized hDnmt1. NK: negative control. 
In order to identify single VHHs specific for the appropriate antigen, 19 (yH2AX ELISA 3. 
panning) to 48 (Dnmt1 ELISA 1. panning) single phage clones were tested in phage ELISA. The 
results in Figure 30 to Figure 32 show, that all libraries contain antigen specific VHHs. The 
percentage of antigen specific clones (signal intensity defined empirically as > 1) varies 
between 5 % and 51 % (see Table 28). 
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Table 28: Overview of antigen specific clones identified in phage ELISA. 
 
ANTIGEN SPECIFIC CLONES IDENTIFIED IN PHAGE ELISA 
(%) 
HIV-1 3. panning 20 
yH2AX 3. panning 37 
HIV-1 Nterm 2. panning 5 
GST 1. panning 51 
Dnmt1 1. panning 10 
Dnmt1 2. panning 21 
In order to identify HIV-1 capsid protein specific VHHs 40 single phage clones were tested 
after the third panning round for their specificity to HIV-1 capsid protein (see Figure 30 A). 
The results show that 20 % of the clones recognize HIV-1 capsid protein while none of the 
tested clones recognizes the negative control (GFP). Apparently, the desired enrichment of 
HIV-1 capsid specific VHHs during the panning occurred. 
In Figure 30 B the result of the phage ELISA of selected phage clones after the second 
panning round against the N-terminal domain of HIV-1 capsid protein is depicted. In order to 
select for specific VHHs 40 clones were tested. Although the sequencing results after the 
second panning round (Figure 26 A) imply the selection of just one specific VHH, the phage 
ELISA, however, results in only 5 % positive clones. 
In order to identify GST-specific VHHs, a phage ELISA was performed testing 57 clones 
after the first panning against GST with 51 % of the clones being specific for GST (see Figure 
31 A). This result is in accordance with the panning results with the phage titer for the 
negative control being 50 % of the phage titer for the antigen specific phages (see Figure 20 
D). 
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Figure 31 B shows the result for the identification of yH2AX specific VHHs with 19 single 
phage clones being tested against yH2AX-BSA and GFP as negative control after the third 
panning round. The result shows that 37 % of the tested clones specifically recognize yH2AX-
BSA. This is contrary to the phage display results shown in Figure 21 B with the phage titer 
being almost zero for the negative control. 
Figure 32 shows the phage ELISA results of selected phage clones after the solid phase 
panning against hDnmt1. Clearly, more antigen specific clones can be identified after the 
second panning round (21 %) than after the first panning round (10 %). Within these two 
phage ELISA experiments no negative controls were performed, however, to verify the 
specificity for hDnmt1 all positive phages from the first and second panning were repeatedly 
tested including GFP as a negative control (Figure 32 C). The result shows that all VHHs 
identified in the first phage ELISA are specific for hDnmt1 and do not recognize GFP. 
3.1.5.1 Sequence analysis after Phage ELISA 
Phage ELISA enables the identification of antigen specific VHHs. To analyze the protein 
sequences of antigen specific VHHs, the DNA of 5 - 31 single clones obtained in phage ELISA 
was subjected to sequence analysis. The first phage ELISA performed during this thesis was 
the phage ELISA to identify HIV-1 specific VHHs (see Figure 30 A). It was not clear which 
threshold level regarding the signal intensity needs to be defined in order to select positive 
clones, hence, the DNA of all clones tested in ELISA was sequenced and analyzed resulting in 
a threshold of OD450nm = 1 for subsequent phage ELISA experiments. 
Interestingly, all sequences of positive clones derived from phage ELISA shown in Figure 35 
to Figure 38 are VHHs and show the characteristic hydrophilic amino acid substitutions (the 
so called hallmark residues) in the FR2 region at positions 37, 44, 45, 47. In summary, the 
results show, that only 43 % of the antigen specific VHHs identified in phage ELISA possess an 
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extended CDR3. 62 % of the VHHs with extended CDR3s possess at least one additional 
cysteine residue independently of the antigen or panning round. 
  
Figure 33: Occurrence of CDR3 lengths of antigen specific VHHs selected via phage ELISA. VHH and VH 
sequences from clones sequenced after the panning rounds (see Figure 24 - Figure 28). Numbering after Kabat, 
1991. 
The VHH sequence analysis of positive clones selected in phage ELISA against HIV-1 capsid 
protein (Figure 34) shows an enrichment of six different sequences: e.g. HIV-1_3p_ELISA#2 
(HIV#2), HIV-1_3p_ELISA#1 (HIV#1), HIV-1_3p_ELISA#9 (HIV#9), HIV-1_3p_ELISA#10 
(HIV#10), HIV-1_3p_ELISA#12 (HIV#12) HIV-1_3p_ELISA#13 (HIV#13) and HIV-1_3p_ELISA 
#19 (HIV#19). The sequences of HIV#1 and HIV#9 are highly similar; however, they vary by 
one amino acid residue in the CDR3, by three amino acid residues in the CDR2 and by one 
amino acid residue in the CDR1. The differences in the CDR3 is due to the use of different D 
segments during VDJ recombination, the differences in CDR1 and CDR2 could be the result of 
somatic hypermutation during affinity maturation. In addition, HIV-1_3p_ELISA#26 has the 
same CDR3 as HIV#9, but differs in CDR2 by one aminoacid residue which may be explained 
by somatic hypermutation, as well. All identified sequences can also be found within the 
sequences after the 1. and the 3. panning round against HIV-1 capsid protein (see Figure 25). 
Again, as shown in the sequence analysis after the panning rounds, all HIV-1 capsid protein 
specific VHHs comprise very short CDR3s with no additional cysteine residues. In contrast, 
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87,5 % of the VHH domains selected against the N-terminal domain of HIV-1 capsid protein 
comprise an extended CDR3 and two additional cysteine residues in their CDR3, e.g. HIV-1-N-
term_2p_ELISA#1 (HIV-Nterm#1) (see Figure 36).  
The VHH sequence analysis of positive clones derived after phage ELISA against yH2AX-BSA in 
Figure 35 shows an enrichment of one sequence e.g. γH2AX_3p_ELISA#3. This sequence 
contains two additional cysteins located in the CDR2 and CDR3. Interestingly, this sequence 
can be found after the 3. panning round already (see Figure 24 C), verifying positive selection 
of antigen specific VHHs during phage display. Another CDR3 is enriched (e.g. 
γH2AX_3p_ELISA#4), however, these sequences do not have additional cysteine residues 
and differ in CDR1 and CDR2 which can be explained by the use of the same D segment but 
different V segments during VDJ-recombination. 
In Figure 37 the VHH sequence alignments of single positive clones for GST are depicted with 
two enriched sequences: e.g. GST_1p_ELISA#35 and e.g. GST_1p_ELISA#25. Both enriched 
sequences neither possess an extended CDR3 nor additional cysteine residues. In addition, 
several sequence pairs seem very similar, e.g. GST_1p_ELISA#1 and GST_1p_ELISA#39 or 
GST_1p_ELISA#23 and GST_1p_ELISA#50. However, they have slight sequence difference in 
CDR3 (one amino acid residue) and CDR2. The differences in the CDR3s may be explained by 
the use of different D segments during VDJ recombination while the differences in the CDR2s 
may be explained by somatic hypermutation since there is no sequence difference within 
the CDR1s implying the use of different V segments. 
Figure 38 shows the VHH sequence alignments of single positive clones for hDnmt1 resulting 
in two enriched sequences: e.g. Dnmt1_1p_ELISA#26 and e.g. Dnmt1_1p_ELISA#30. Both 
enriched sequences possess an extended CDR3, but only one of the sequences has two 
additional cysteine residues. 
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Figure 34: Sequence alignment of VHH amino acid sequences of single positive clones from phage ELISA against HIV-1 capsid protein. Color code: CDR1: magenta, 
CDR2: blue, CDR3: green, hallmark residues: violet, identical sequences are marked with a red bar. Numbering after Kabat, 1991. 
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Figure 35: Sequence alignment of VHH amino acid sequences of single positive clones from phage ELISA against γH2AX-BSA. Color code: CDR1: magenta, CDR2: blue, 
CDR3: green, hallmark residues: violet, identical sequences are marked with a red bar. Numbering after Kabat, 1991. 
 
Figure 36: Sequence alignment of VHH amino acid sequences of single positive clones from phage ELISA against N-terminus of HIV-1 capsid protein. Color code: 
CDR1: magenta, CDR2: blue, CDR3: green, hallmark residues: violet, identical sequences are marked with a red bar. Numbering after Kabat, 1991. 
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Figure 37: Sequence alignment of VHH amino acid sequences of single positive clones from phage ELISA against GST. Color code: CDR1: magenta, CDR2: blue, CDR3: 
green, hallmark residues: violet, identical sequences are marked with a red bar. Numbering after Kabat, 1991. 
 
Figure 38: Sequence alignment of VHH amino acid sequences of single positive clones from phage ELISA against hDnmt1. Color code: CDR1: magenta, CDR2: blue, 
CDR3: green, hallmark residues: violet, identical sequences are marked with a red bar. Numbering after Kabat, 1991. 
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3.1.6 Selection of antigen specific VHHs by the F2H-Assay 
Even though the method phage ELISA on immobilized antigens is quick and convenient, 
especially because of the signal amplification which occurs due to the detection of multiple 
copies of pVIII on the phage surface using a specific antibody, the antigen presentation may 
not necessarily be beneficial or representative for the selection of antigen specific VHHs 
regarding their downstream application as Chromobody in living cells. As described in 3.1.4.2 
immobilized antigens may be denatured in vitro resulting in VHHs recognizing the denatured 
antigen only but not the native folded antigen found inside living cells. 
In order to select antigen specific VHHs which recognize the native folded antigen the 
native panning described in 3.1.4.2 was combined with the fluorescent-two hybrid (F2H) 
assay developed by Zolghadr et al. in 2008. The F2H assay enables the visualization of 
protein-protein interactions in single living cells making it well suited to screen for antigen 
specific VHHs. The method is based on a Baby-Hamster-Kidney (BHK) cell line stably 
expressing 200 - 1000 copies of a plasmid carrying 256 copies of a protein-protein 
interaction biosensor (lac operator sequence) at a single chromosomal site. By co-
transfection of a so-called bait which is immobilized to the protein-protein interaction 
biosensor (PPIB) via the lac repressor (lacI) and visualized as a nuclear spot and a prey, a 
protein-protein interaction can be made visible in living cells by fluorescent read out (Figure 
39) (Zolghadr et al., 2008). 
The whole VHH repertoire after the second native panning round against hDnmt1 
described in 3.1.4.2 was cloned into a mammalian expression vector containing a red 
fluorescent protein via PCR. Throughout this thesis for all (monomeric) red fluorescent 
proteins, irrespective of which specific derivate was used (i.e. mRFP, mCherry, mPlum, 
mRFPruby or TagRFP) the acronym RFP will be used. The resulting library, representing the 
prey, contains the VHH repertoire after the second panning round in fusion to RFP and is 
called Dnmt1-Chromobody F2H library (Figure 39 B) 
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Figure 39: Schematic outline of the F2H assay. (A) Bait fusion protein comprising the lacI domain fused to 
GFP-hDnmt1. (B) Prey fusion protein comprising the hDnmt1-Chromobody library. (C) Principle of F2H assay: 
the lacI domain mediates the binding to the lac operator array resulting in a fluorescent spot in the nucleus. 
Upon interaction with the bait protein, it becomes enriched at the same spot resulting in co-localization of the 
fluorescent signals visible as yellow spot. If bait and prey do not interact, the lac operator array is visualized by 
the bait protein only resulting in a green spot. Modified after Zolghadr et al., 2008. 
To select Chromobodies specifically recognizing hDnmt1, the BHK cell line described 
above was co-transfected with 96 individual clones of the hDnmt1-Chromobody F2H library 
each together with lacI-GFP-hDnmt1. The over expressed GFP-hDnmt1-fusion protein binds 
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to the lac operator array, mediated by the lacI, which then becomes visible due to the focal 
enrichment of the GFP fluorescence. Chromobodies which specifically bind to hDnmt1 co-
localize with GFP-hDnmt1 resulting in co-localization of the fluorescent signals of RFP and 
GFP. Figure 40 exemplarily shows 4 hDnmt1 specific Chromobodies (hDnmt1-cb-mCh): 2pA7, 
2pC1, 2pC6 and 2pH11. In contrast to the hDnmt1 specific VHHs selected in solid phase 
panning, with no Chromobody being functional inside living cells, VHHs specific for hDnmt1 
selected in native panning are functional in living cells. These results clearly demonstrate the 
importance of this newly designed and established screening method. 
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Figure 40: Exemplary results of F2H screen of hDnmt1 specific Chromobodies. (A) Transgenic BHK cells 
containing a chromosomal lac operator array were co-transfected with lacI-GFP-hDnmt1 (GFP-hDnmt1) and 
hDnmt1-Chromobody-RFP (hDnmt1-cb-mCh). The lacI part of the GFP-hDnmt1 construct mediates the binding 
to the lac operator array resulting in a spot (highlighted by arrowheads in upper row). The specific binding of 
the hDnmt1-Chromobodies to GFP-Dnmt1 can be detected by co-localization of the fluorescence signals of RFP 
and GFP (highlighted by arrowheads in middle row). (B) As negative control these transgenic BHK cells were co-
transfected with GFP-lacI without being fused to hDnmt1 and with the hDnmt1-Chromobody-RFP (here 
exemplarily shown for hDnmt1-Chromobody-RFP 2pA7mCh). The GFP-lacI binds to the lac operator array 
resulting in a spot (highlighted by arrowheads). Since the hDnmt1-part is missing, the hDnmt1 Chromobody is 
dispersedly distributed throughout the nucleus indicating no interaction. Scale bars 5 µm. 
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3.1.6.1 Sequence analysis after Fluorescence-2 Hybrid Assay 
In contrast to phage ELISA, the F2H assay enables the identification of antigen specific 
VHHs in vivo. To analyze the protein sequences of the antigen specific clones, the 4 positive 
clones obtained in the F2H screen were subjected to sequence analysis. Figure 41 shows the 
sequence alignments of the positive clones of the F2H screen against hDnmt1 with all 
sequences including the VHH hallmark residues. In addition, the result shows that no 
sequence is enriched, however, two sequences, hDnmt1-mCh_2pA7 and hDnmt1-
mCh_2pC1, are highly similar and differ in four amino acid residues, only. Those two 
sequences and the sequence of hDnmt1-mCh_2pH1 have neither an extended CDR3 nor an 
additional cysteine residue. In contrast, the sequence of hDnmt1-mCh_2pC6 has an 
extended CDR3 and two additional cysteine residues. 
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Figure 41: Sequence alignment of VHH amino acid sequences of single positive clones against hDnmt1 from F2H screen. Color code: CDR1: magenta, CDR2: blue, 
CDR3: green, hallmark residues: violet. Numbering after Kabat, 1991. 
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3.2 Characterization of antigen specific VHHs 
The main focus in the first part of this thesis was to optimize the different steps involved 
in generating antigen specific VHHs. The second part focuses on the characterization of 
antigen specific VHHs. After the successful selection of antigen specific VHHs using phage 
display and the identification via phage ELISA, they were further analyzed regarding their 
binding characteristics and their applicability in different biochemical and intracellular 
approaches in order to study their usability as Nanotraps and Chromobodies. 
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3.2.1 Biochemical characterization 
The first characterization step was the biochemical characterization including epitope 
mapping, immunoprecipitation experiments and solubility tests. 
3.2.1.1 Epitope mapping 
VHHs, like all antibodies or antibody fragments, recognize specific parts of an antigen 
which is referred to as epitope (Bonavida and Sercarz, 1971). The knowledge about the 
epitope of an antibody provides valuable information useful for disease prevention, 
diagnosis and treatment. It allows for predictions of potential biological interference upon 
binding, e.g. the influence on catalytic activity or the correct folding or the disturbance of an 
interaction with another protein. Hence, epitope mapping is an important step in 
characterizing antibodies or recombinant antibody fragments. 
Primarily, the HIV-CA-specific VHHs were analyzed with respect to their epitope 
specificity. There are several methods available to map an antibody´s epitope, Here, phage 
ELISA and Dot Blot were employed. In a first test, HIV-1 capsid specific VHHs were tested in a 
phage ELISA experiment as described in 3.1.5 using fullength HIV-1 capsid protein in 
combination with truncated versions thereof (see Figure 42) (C-terminal domain (amino acid 
residues 146-231) and N-terminal domain (amino acid residues 1-146 or 1-151); proteins 
kindly provided by Vanda Lux, AG Hans-Georg Kräusslich, University hospital Heidelberg). 
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Figure 42: HIV-1 capsid protein domains and truncated versions tested in phage ELISA. 
The result in Figure 43 shows that all phages displaying a HIV specific VHH fragment at 
their surface recognize the fullength version of the HIV-1 capsid protein. However, phages 
derived from the panning against the fullength HIV-1 capsid protein (HIV#1, HIV#2, HIV#9, 
HIV#12 and HIV #19) recognize specifically the isolated C-terminal domain of the HIV-1 
capsid protein but not the isolated N-terminal part of the protein. On the other side, phages 
derived from the panning against the N-terminal part of the HIV-1 capsid protein (HIV-
Nterm#1) recognize beside the fullength HIV-1 capsid protein he isolated N-terminal domain 
but do not recognize the isolated C-terminal part of the HIV-1 capsid protein. 
3 Results 
 
120 
 
 
Figure 43: Epitope mapping of HIV-1 capsid protein specific VHHs by phage ELISA. Phages comprising 
clones HIV#1, HIV#2, HIV#9, HIV#12, HIV#19 and HIV-Nterm#1 were tested on different versions of the HIV-1 
capsid protein. All clones specifically bind to the fullength HIV-1 capsid protein. The clones HIV#1, HIV#2, 
HIV#9, HIV#12 and HIV#19 specifically recognize the C-terminal part of the HIV-1 capsid protein and do not 
recognize the N-terminal part of the protein. In contrast, HIV-Nterm#1 does not recognize the C-terminal 
domain but does recognize the N-terminal domain of the HIV-1 capsid protein. The negative control GFP was 
not recognized by any of the VHHs. The experiment was performed in duplicates; the error bars represent the 
standard deviation of the duplicate values. Numbers given in parentheses correspond to amino acid residues. 
In order to further refine the epitope of the VHHs specific for the C-terminal domain in 
vitro a phage ELISA was performed using overlapping peptides derived from the C-terminal 
domain: one 18-mer peptide, five overlapping 15-mer peptides and one 14-mer peptide (see 
Figure 44) (peptides kindly provided by Vanda Lux, AG Hans-Georg Kräusslich, University 
hospital Heidelberg). In addition, two truncated versions of the fullength HIV-1 capsid 
protein were tested and the HIV-1 capsid protein N-terminal domain was used as negative 
control. 
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Figure 44: HIV-1 capsid protein domains and peptides tested in Dot Blot. 
The results shown in Figure 45 show that all tested VHHs specifically recognize the 
truncated versions of the fullength HIV-1 capsid protein amino acid residues 1-220 and 
residues 1-207. In contrast, none of the peptides are recognized. The slight differences in 
signal intensity in comparison to Figure 43, especially regarding HIV#19, may be due to 
fluctuations in phage production within the two experiments. 
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Figure 45: Epitope mapping of VHHs specific for the C-terminal domain of the HIV-1 capsid protein by 
phage ELISA. Phages comprising clones specific for the C-terminal domain of HIV-1 capsid protein were tested 
for their binding specificity on different peptides of the HIV-1 capsid protein C-terminal domain. All clones 
specifically bind to the truncated versions 1-220 and 1-207 while none of the clones recognizes the N-terminal 
domain of the HIV-1 capsid protein (1-146). Additionally, none of the clones recognizes one of the peptides. 
Numbers given correspond to amino acid residues. 
As shown above, phage ELISA is a quick and convenient method to analyze binding 
specificities of VHHs in vitro. However, this method is depending on phage production which 
can vary dramatically in between different experiments. In addition, as described in 3.1.4.2 
protein molecules when absorbed on polystyrene undergo conformational changes; hence, 
epitopes may become partially denatured. In order to avoid these drawbacks, another 
approach to refine the epitope was performed during this thesis: Dot Blot analysis. Dot Blot 
is a more native-like approach from both perspectives, nanobody and antigen, since the 
nanobody is recombinantly purified and the antigen is not immobilized on polystyrene. In 
brief, truncated versions of the C-terminal domain of the HIV-1 capsid protein were spotted 
on nitrocellulose and detected directly with recombinant produced and FITC labeled VHHs. 
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Figure 46: Epitope mapping of VHHs specific for the C-terminal domain of the HIV-1 capsid protein by Dot 
Blot analysis. Recombinant produced and FITC labeled VHHs specific for the C-terminal domain of HIV-1 capsid 
protein were tested for their binding specificity on different truncated versions of the HIV-1 capsid protein C-
terminal domain. All clones specifically bind to the fullength HIV-1 capsid protein and the truncated versions 1-
220 and 1-207. In addition, all clones recognize the deletion mutant delta 207-220. The truncated version 1-177 
is not recognized, except HIV#12 showing a weak signal. None of the clones recognizes the N-terminal domain 
of the HIV-1 capsid protein (1-151). Numbers correspond to amino acid residues. 
The results in Figure 46 show a refining of the epitope of the C-terminal specific VHHs. 
With all tested clones a signal can be obtained with the fullength HIV-1 capsid protein and 
the truncated versions 1-220 and 1-207 which confirms the result in Figure 45. In addition, 
the result shows that all VHHs recognize a mutant of the fullength HIV-1 capsid protein with 
amino acid residues 207-220 deleted. The truncated version 1-177 is not recognized except 
for HIV#12 showing weak signals. The N-terminal domain was used as negative control and is 
not recognize by any of the VHHs. The results from the Dot Blot analysis indicate an epitope 
between amino acid residues 178-206. This experiment was also performed with peptides 
spotted on the nitrocellulose membrane; however, no signals were obtained (data not 
shown). The results indicate that the HIV-1 capsid protein VHHs rather bind to a 
conformational epitope than a linear epitope. 
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3.2.1.2 Immunoprecipitation 
The two methods described above are highly suitable to map and refine the epitope of 
antibodies and antibody fragments such as VHHs. However, methods employing phages also 
have drawbacks regarding the presentation of the VHH on the tip of a phage which may lead 
to misfolding of the VHH domain and, as a consequence, influence the antigen binding. In 
order to avoid these drawbacks and to confirm the specificity of VHHs they were further 
characterized by immunoprecipitation (IP). For this purpose, VHHs were expressed in E. coli 
and purified using IMAC and size exclusion chromatography. Then, they were covalently 
coupled to NHS-Sepharose beads and used for IP. In this format, specific VHHs are referred to 
as Nanotraps. During this thesis the following Nanotraps were analyzed in IP experiments: 
HIV#1 (HIV-Trap#1), HIV#2 (HIV-Trap#2), HIV#9 (HIV-Trap#9), HIV#12 (HIV-Trap#12) and 
GST_1p_ELISA#35 (GST-Trap). HIV#19 was not further analyzed since the expression levels in 
E. coli were too low, which may be explained by the two additional cysteine residues. 
Having been focused on the development and optimization of novel screening processes 
and the establishment of a working pipeline some of the identified antigen specific VHHs 
during this work became autonomous projects subsequently conducted by coworkers and 
collaborators. Hence, in the following own results are shown for only two (HIV-1 capsid and 
GST) of the five initial targets. 
In order to analyze the binding specificity of the HIV-Traps, lysates from HEK293T cells 
expressing HIV-1-GagGFP (85kDa) with the capsid protein as an internal domain of the Gag 
precursor protein were subjected to immunoprecipitation with the HIV-Traps. Input (I) and 
bound fractions (B) were analyzed by SDS PAGE and immunoblot analysis. 
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Figure 47: Immunoprecipitation with HIV-Traps. Cell extracts of HIV-1-GagGFP producing HEK293T cells 
were precipitated with each HIV-Trap. 2 % of input (I) and 20 % of bound fraction (B) were separated by SDS-
PAGE followed by (A) immunoblot analysis. Predicted molecular weight of HIV-1-GagGFP (85 kDa) is marked by 
an arrow. (B) Quantitative analysis of immunoprecipitation experiment. The experiment was performed in 
duplicates; the error bars represent the standard deviation of the technical replicates. 
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The results in Figure 47 A show, that all HIV-Traps precipitate the expressed HIV-1-
GagGFP. The quantitative analyses (Figure 47 B) reveal that HIV-Trap#1 shows the best 
performance whereas HIV-Trap#12 only precipitates small amounts of antigen. 
The specificity of the GST-Trap was tested in two different approaches. Initially, 
recombinant GST protein was used for immunoprecipitation with the GST-Trap. Input (I), 
non-bound (FT) and bound fractions (B) were analyzed by SDS PAGE with subsequent 
Coomassie staining. 
 
Figure 48: Immunoprecipitation with GST-Trap. Recombinant GST and GFP were precipitated with the 
GST-Trap. 2 µg GST (I), 20 % non-bound fraction (FT) and 100 % bound fraction (B) were separated by SDS-PAGE 
followed by Coomassie staining. Predicted molecular weight of GST (26 kDa) and GFP (27 kDa) is marked by an 
arrow. 
The result in Figure 48 shows that the GST-Trap specifically precipitates recombinant 
GST, but does not recognize GFP. However, to verify that the GST-Trap does not bind 
unspecifically to other proteins, lysates from GST expressing E. coli were subjected to 
immunoprecipitation with the GST-Trap in a second approach. Input (I) and bound fractions 
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(B) were analyzed by SDS PAGE with subsequent Coomassie staining and immunoblot 
analysis. 
 
Figure 49: Immunoprecipitation with GST-Trap. E. coli cell extracts expressing GST were precipitated with 
the GST-Trap. 1 % of input (I), 1 % non-bound fraction (FT) and 30 % bound fraction (B) were separated by SDS-
PAGE followed by (A) Coomassie staining and (B) immunoblot analysis. Predicted molecular weight of GST (26 
kDa) is marked by an arrow. 
The result in Figure 49 confirms that the GST-Trap specifically recognizes GST. The 
additional band detected in the bound lane may result from degradation products of GST. 
3.2.1.3 Solubility-Test 
Not only the recombinant production in E. coli requires solubility of VHHs but it is also an 
important requirement in regard to their functionality as Chromobodies in mammalian cells. 
In general, VHHs feature high stability and solubility (Muyldermans, 2001), however, during 
the work for this thesis aggregation and poor expression of VHHs was observed in several 
cases. Different factors like additional cysteine residues and the length of the CDR3 may 
influence the solubility of Chromobodies inside living mammalian cells (Conrath et al., 2003). 
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Therefore, three already described and functional Chromobodies, GFP-Chromobody, Lamin-
Chromobody and Cytokeratin-Chromobody (Rothbauer et al., 2006), were analyzed 
regarding additional cysteine residues and their CDR3 length.
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Figure 50: Alignment of three already described VHH sequences. All three VHHs have no additional cysteine and no extended CDR3. 
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The alignment of the VHH sequences shows, that none of the three VHHs has an 
additional cysteine residue or an extended CDR3 (Figure 50) which is in accordance to the 
already published data (Rothbauer et al., 2006) showing their functionality in living cells. 
During this thesis, however, the functionality of VHHs in mammalian cells was analyzed 
regarding the localization of the fluorescent protein. In brief, GFP-Chromobody, Lamin-
Chromobody and Cytokeratin-Chromobody were cloned in a vector containing an N- or C-
terminal fluorescent protein, respectively (see Figure 51). These constructs were expressed 
in HEK293T cells and analyzed. As transfection control a vector containing GFP only was 
used. 
 
Figure 51: Chromobody constructs used in functionality tests. 
First, the transfection rate was determined by counting transfected and untransfected 
cells (Table 29). The transfection rates show, that the Cytokeratin-Chromobody and the 
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Lamin-Chromobody are both expressed in lower levels if the fluorescent protein is localized 
C-terminal. In contrast, the GFP-Chromobody is expressed well independent of the 
localization of the fluorescent protein. 
Table 29: Comparison of transfection rate of Chromobodies. For each construct 50 cells were analyzed. 
 TRANSFECTION RATE (%) 
GFP-VHH-mRFP 80 
mcherry-GFP-VHH 85 
Lamin-VHH-GFP 50 
GFP-Lamin-VHH 30 
Cyto-VHH-GFP 80 
GFP-Cyto-VHH 5 
GFP (positive control) 80 
After the determination of the transfection rate, the Chromobodies were analyzed 
regarding their solubility in immunoblot. In Figure 52 the results of the solubility tests are 
depicted. The results show, that the Cytokeratin-Chromobody (Figure 52 A) is expressed 
poorly if the fluorescent fusion protein is N-terminal fused, but well expressed with the 
fluorescent fusion protein being C-terminal fused. However, the level of the soluble fraction 
(SN) of the Cytokeratin-Chromobody is 50 %, independent of the localization of the 
fluorescent protein. The Lamin-Chromobody (Figure 52 B) with N-terminal fused GFP is not 
expressed at all, while the C-terminal fusion is expressed well. The level of the soluble 
fraction (SN) is 70 %. In contrast, the GFP-Chromobody (Figure 52 C) is 100 % soluble and is 
expressed well independent of the localization of the fluorescent protein. The detection of 
endogenous PCNA was performed as control for the complete lysis of the cells.  
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Figure 52: Solubility test with Chromobodies. (A) HEK293T cell extract expressing Cytokeratin-
Chromobody with either C-terminal or N-terminal GFP were lysed and 1 % of pellet (P) and 1 % of supernatant 
(SN) separated by SDS-PAGE followed by immunoblot analysis. (B) HEK293T cell extract expressing Lamin-
Chromobody with either C-terminal or N-terminal GFP were lysed and 1 % of pellet (P) and 1 % of supernatant 
(SN) separated by SDS-PAGE followed by immunoblot analysis. (C) HEK293T cell extract expressing GFP-
Chromobody with either C-terminal mRFP or N-terminal mcherry were lysed and 1 % of pellet (P) ad 1 % of 
supernatant (SN) separated by SDS-PAGE followed by immunoblot analysis. Predicted molecular weight of 
Chromobody (42 kDa) and PCNA (29 kDa) is marked by an arrow. Endogenous level of PCNA was detected by an 
anti-PCNA antibody as positive control. 
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The results of the analyses of the Chromobodies show that solubility of VHHs depends 
not only on the occurrence of additional cysteine residues and extended CDR3s but also on 
the position of the fluorescent protein (N- versus C-terminal). 
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3.2.2 Intracellular characterization 
After the biochemical characterization of antigen specific VHHs, their capacity to 
recognize and bind antigens in living cells was analyzed. To this end functionality tests and 
immunofluorescence were performed. 
3.2.2.1 Functionality test 
As described in 3.2.1.3, the solubility of Chromobodies is an inevitable requirement not 
only for the production in E. coli but also for their functionality in living mammalian cells. 
Therefore, in addition to the solubility test using cell extracts of HEK293T expressing 
Chromobodies (3.2.1.3), the Chromobodies were also tested for their functionality in HeLa 
Kyoto cells with regard to the C- or N-terminal localization of the fluorescent protein. To this 
end, HeLa Kyoto cells were transfected with the GFP-Chromobody, the Lamin-Chromobody 
and the Cytokeratin-Chromobody each fused N- or C-terminal to a fluorescent protein and 
fixed. 
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Figure 53: Functionality test of GFP-Chromobody. (A) GFP-CB-mRFP colocalizes with GFP-PCNA at 
replication foci. (B) mcherry-GFP-CB colocalizes with GFP-PCNA at replication foci. Scale bars 5 µm. 
The GFP-Chromobody colocalizes with GFP-PCNA independent of the localization of the 
fluorescent protein (Figure 53). This result is in accordance with the solubility test in 3.2.1.3 
showing that both variants of the GFP-Chromobody are soluble and show comparable 
expression levels. However, this is contrary to previous observations which have indicated a 
functional dependency on the N- or C-terminal localization of the fluorescent protein 
(Leonhardt and Rothbauer, 2005). The main difference between these two opposite results 
is the length and the composition of the linker between the VHH fragment and the 
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fluorescent protein. Therefore, the results show that the position of the fluorescent protein 
within the Chromobody construct does not necessarily influence the functionality of the 
GFP-Chromobody. 
 
Figure 54: Functionality test of Lamin-Chromobody. (A) Lamin-CB-GFP highlights the nuclear rim structure 
that is characteristic for the nuclear lamina. (B) GFP-Lamin-CB highlights the nuclear rim structure that is 
characteristic for the nuclear lamina. In addition, aggregates of the Chromobody are visible. Scal bars 5 µm. 
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The Lamin-Chromobody colocalizes with nuclear lamina independent of the localization 
of the fluorescent protein (Figure 54). However, the GFP-Lamin-CB construct in Figure 54 B 
shows aggregates in the cytoplasm of the cells. Hence, the N-terminal fusion of the 
fluorescent protein negatively influences the functionality of the Lamin-Chromobody. 
 
Figure 55: Functionality test of Cytokeratin-Chromobody. (A) Cytokeratin-CB-GFP highlights the nuclear 
cytoplasmic filaments. (B) GFP-Cytokeratin-CB aggregates. Scale bars 5 µm. 
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The Cytokeratin-Chromobody colocalizes with cytoplasmic filaments if the fluorescent 
protein is localized at the C-terminus (Figure 55 A). However, the positioning of the GFP at 
the N-terminus of the Cytokeratin-Chromobody construct leads to a very low expression, 
formation of aggregates and no staining of the antigen structure. Therefore fusion with the 
fluorescent protein does influence the functionality of the Cytokeratin-Chromobody. 
In general, VHHs are characterized by their high stability and solubility (Muyldermans, 
2001) which previously has also been showed in living mammalian cells (Rothbauer et al., 
2006). However, the results depicted above illustrate that VHH domains fused to a 
fluorescent protein may have a tendency to aggregate which may be due to the 
overexpression of the fusion protein, the position of the fluorescence protein or the 
presence/number of cysteine residues. Moreover, the length and the amino acid 
composition of the linker between VHH fragment and the fluorescent protein are crucial. 
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4 Discussion 
Antibodies are key components applied in basic research, diagnostics and therapy. They 
are powerful tools to study and to measure the distribution and localization of countless 
different antigens including proteins, posttranslational modifications or chemical entities. 
However, in order to study and understand continuous dynamic processes on a cellular level, 
data on dynamic localization, modification and interaction of cellular components are 
necessary. Here, the use of conventional antibodies is rather limited due to their complex 
structure which interferes with their application within living cells. 
Naturally occurring heavy chain antibodies (hcAbs) derived from Camelidae are an 
attractive alternative to conventional and recombinant antibodies. In hcAbs, antigen binding 
is mediated through a single domain, referred to as VHH (variable domain of heavy chain 
antibodies). VHHs are characterized by a very small size (~ 15 kDa), extreme stability (van der 
Linden et al., 1999) (Arbabi Ghahroudi et al., 1997) and high solubility (Muyldermans, 2001). 
In addition, VHHs have been shown to bind epitopes inaccessible for conventional antibodies 
(Lauwereys et al., 1998) (De Genst et al., 2006). Altogether, these features render VHHs 
versatile tools for diverse applications in basic research, diagnostics and therapy. 
The main objective of this thesis was to generate and characterize antigen specific VHHs 
functional in biochemical and intracellular applications. The VHHs were generated against a 
broad range of antigens from a peptide (yH2AX) to a component of a virus particle (HIV-1 
capsid protein), a middle sized protein (PCNA), a fusion protein (ß-Catenin-GST) and a large 
protein (hDnmt1).  
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4.1 VHH libraries 
The first step for a successful selection of antigen specific VHHs is the generation of a high 
quality primary VHH library in terms of diversity and size, ideally comprising 10
5 - 109 clones 
(Arbabi Ghahroudi et al., 1997). Such libraries can be obtained by using either immunized 
animals to produce an immune library or non-immunized animals to produce a naïve library. 
The use of libraries derived from immunized animals is advantageous since library sizes of 
106 - 107 clones is sufficient to select antigen specific VHHs (Muyldermans, 2001). In addition, 
the selection of high affinity clones against the target antigen is facilitated (Smith et al., 
2005) since the exposure to the antigen elicits the production of antigen-specific antibodies 
and somatic hypermutation takes place resulting in the creation of antibodies with improved 
affinity (Hoogenboom, 2005) (Ponsel et al., 2011). High affinity of a VHH to its antigen is vital 
especially when used as Nanotrap in (co-) immunoprecipitations ((Co-) IPs). In this 
application the binding to the antigen needs to be strong and specific in order to enable the 
isolation of the protein of interest quantitatively and in a very short time. This proves 
particular important when working with sensitive proteins (with regard to temperature or 
pH) with high tendency for degradation, like hDnmt1 for example. 
4.1.1 Immunogenicity of Antigens 
The generation of a comprehensive library from immunized alpacas requires an immune 
response against the immunized antigen, first. Naturally not all antigens are immunogenic: 
the immune system discriminates not only between the body´s own and foreign molecules 
but also small, less complex antigens such as peptides are often non-immunogenic and do 
not elicit sufficient immune response (Stanley, 2002). Therefore, to stimulate an immune 
response, most antigens require to be injected in a mixture that enhances the 
immunogenicity of an antigen known as adjuvant (Janeway et al., 2001). The most 
commonly used adjuvant is Freund´s adjuvant which contains heat-inactivated mycobacteria 
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in a mineral oil-surfactant mixture (Freund, 1956). Even being widely used, Freund´s 
adjuvant is associated with a severe and painful inflammatory response (Bennett et al., 
1992). Hence, for the immunization of the alpacas an alternative adjuvant, Gerbu adjuvant, 
was used. Gerbu adjuvant is tolerated well, but is disadvantageous in terms of the 
production of antibodies in equal quality to those of other adjuvants (Stills, 2005). Since 
adjuvants enhance immune response but cannot themselves render antigens immunogenic, 
small antigens need to be conjugated to a large carrier protein in order to elicit an immune 
response. The most commonly used carriers are keyhole limpet hemocyanin (KLH), bovine 
serum albumin (BSA) and ovalbumin (OVA). Since KLH is evolutionary more remote from 
mammalian proteins and contains a high number of primary amines which enables the 
coupling of a high number of peptides (Grant, 2003) it was used as carrier to conjugate 
yH2AX.  
The immune response of our alpacas was monitored in three exemplary serum tests: for 
the large protein hDnmt1, the fusionprotein ß-Catenin-GST and the peptide yH2AX. The 
results show that both the large protein hDnmt1 and the fusionprotein ß-Catenin-GST elicit 
an immune response in the alpaca. Hence, it can be concluded that the Gerbu adjuvant is 
sufficient to elicit an immune response in alpacas, in general. The peptide yH2AX, however, 
does not trigger an immune response - even immunized in the KLH-conjugated form. 
Although VHHs were reported to bind haptens (Ladenson et al., 2006) they have a strong 
preference for conformational epitopes (Thys et al., 2011) which peptides are unlikely to 
produce (Brown et al., 2011). Conformational epitopes are mostly formed by native proteins 
(Horsfall et al., 1991) when the antigen is available in its native conformation. Therefore, the 
immunization of alpacas with peptides has two major drawbacks: the less efficient immune 
response and the preference for a native conformation of the antigen. The ability to 
recognize native proteins is vital especially for the application of VHHs in living cells as 
Chromobody. 
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During this thesis and in previous reports, Chromobodies functional in living cells were 
successfully generated against human DNA Methyltransferase 1 (hDnmt1), proliferating cell 
nuclear antigen (PCNA) (Burgess et al., 2012), HIV-1 capsid (Helma et al., 2012), green 
fluorescent protein (GFP) (Rothbauer et al., 2006), Lamin Dm0 (Rothbauer et al., 2006) and 
Cytokeratin 8 (Rothbauer et al., 2006) while VHHs recognizing peptides could not be 
generated. These results suggest that the size of the antigen and the foreignness influences 
the immune response in alpacas. 
4.1.2 VHH Library Size and Diversity 
As mentioned above, the size and diversity of a VHH library is a quality feature and the 
starting basis for a successful generation of antigen specific VHHs. To obtain a VHH library, 
peripheral blood lymphocytes (PBL) were used as the source of cDNA synthesis for the VHH 
libraries, even though PBLs are less enriched with antigen-specific VHHs. When working with 
mice or rabbits as antibody source, tissue from the lymph node or spleen is usually used as 
basic raw material (Maass et al., 2007) since upon immunizations, lymphocytes are 
redistributed and remain in lymphoid organs or migrate to tissues rather than circulate in 
peripheral blood (Nduati et al., 2010). However, the use of PBLs is advantageous to lymphoid 
tissue such as spleen or lymph nodes, because PBLs are easily accessible and may be 
sampled repeatedly by taking a blood sample of an animal (Nduati et al., 2010). 
Furthermore, the size of VHH libraries is limited by the B cell and mRNA yield and the 
transformation efficiency of the bacterial host (Ponsel et al., 2011). The applied optimization 
of these procedures resulted in increased library sizes. The first library generated (yH2AX) 
has a size of 6 x 10³ while the final library generated (hDnmt1) contains 1,5 x 105 clones. 
With the generation of larger VHH libraries, the task of assessing their diversity becomes 
more and more complex. Restriction analysis is a quick way to check diversity by the band 
patterns on an agarose gel. However, sequencing is a more preferable method since it also 
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provides additional information which may not be obtained from restriction analysis such as 
frame shifts or stop codons (Carmen and Jermutus, 2002). But, evaluation of large libraries 
by sequencing is costly and time-consuming. Therefore, in order to evaluate the diversity of 
the VHH libraries, ten to fourteen clones from each primary library were sequenced and 
aligned. This analysis showed that 80% of the libraries are highly diverse – only in the yH2AX 
primary VHH library two sequences were found more than once which signifies a reduced 
diversity. However, during this thesis only a small number of sequences was analyzed. In 
order to assess the libraries´ diversity more precisely, a higher number of sequences needs 
to be analyzed. 
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4.2 VHH Selection 
In order to select antigen specific VHHs from the VHH libraries, the phage display method 
was applied. The selection process called panning can be divided in five main steps: 1) 
coating with antigen, 2) blocking of free binding sites, 3) incubation of phages with the 
immobilized antigen, 4) washing and 5) elution (as described in 1.2.2.1). Besides blocking 
with a suitable blocking reagent and stringent washing, the way how the antigen is 
immobilized is of highest importance. In general, antigens are immobilized on a solid surface 
such as magnetic beads (Moghaddam et al., 2003), nitrocellulose (Hawlisch et al., 2001) or 
plastic surfaces like polystyrol tubes (Hust et al., 2002) by passive adsorption which is 
advantageous since a wide range of molecules can be immobilized without prior treatment 
(Willats, 2002). However, passive absorption may result in the immobilized molecule being 
forced out of its functional confirmation (Davies et al., 1994). Hence, antigens may become 
partially denatured, leading to the selection of VHHs which recognize epitopes only present 
in denatured molecules (Chames et al., 2001). As described above, for the application of 
VHHs as Chromobodies in living cells it is essential that the VHH recognizes its antigen in living 
cells available as natively folded protein. The method of passive adsorption in polystyrol 
tubes was successfully used for the selection of HIV-1 capsid specific VHHs (Helma et al., 
2012) and PCNA specific VHHs (Burgess et al., 2012) which both are functional in living cells 
but proofed inadequate for the selection of hDnmt1 specific VHHs functional in living cells. 
4.2.1 A new method to select VHHs for in vivo applications 
In order to address the problem of antigen denaturing upon immobilization, many 
alternative methods are available such as the use of biotinylated antigens which are 
immobilized by streptavidin (Hoogenboom et al., 1998) or the use of a monoclonal antibody 
which is immobilized and binds the antigen for presentation (Verheesen et al., 2006). 
However, these methods are all hampered by the fact that phages tend to unspecifically 
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bind to different kinds of structures such as support surfaces or proteins. In order to 
circumvent these drawbacks, a new selection method based on classical phage display was 
developed: native panning. Here, a GFP-fusion protein is precipitated from mammalian cell 
extract via a GFP-specific VHH. This GFP-specific VHH is coated in a 96 well plate (Pichler et 
al., 2012) resulting in the immobilization of the GFP-fusion protein which is then subjected to 
panning. Besides the native conformation of the presented antigen, also posttranslational 
modifications of the antigen are present in contrast to recombinantly purified proteins 
produced in E. coli. 
The impact of this new method was demonstrated by using the hDnmt1 primary library 
for both panning methods in parallel. The results of the pannings are similar with regard to 
the enrichment of antigen specific VHHs during the panning rounds and the signal-to-noise 
ratio. However, the VHH sequences derived from solid phase panning differed from those of 
the native panning. It can be concluded, that the different presentation of the antigen i.e. 
presentation of denatured versus native antigen, leads to the selection of different VHHs. 
Furthermore, only the VHHs derived from the native panning were functional in living cells, 
whereas the VHHs derived from solid phase panning aggregated in living cells. 
Interestingly, the hDnmt1 specific VHHs selected in native panning do not recognize its 
antigen in immunofluorescence experiments although VHHs have been shown to be 
functional in immunofluorescence analysis (Pichler et al., 2011). It seems that the 
denaturation caused by fixation methods changes the antigen structure in a way which 
hinders the VHH to recognize its antigen. This result shows that the selection method needs 
to be chosen carefully with regard to the presentation of the antigen in the intended 
downstream application of the VHH. 
Different factors influence the functionality of VHHs for cellular applications, such as 
selection method or accessibility of the antigen. In addition, the functionality in vivo is also 
determined by the localization of the fluorescent protein. The results of this thesis showed 
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that the localization of the fluorescent protein may lead to aggregation of the VHH in vivo 
preventing antigen detection. 
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4.3 Compensation of VH-VL combination 
VHHs lack the diversity introduced by VH-VL combination since the VL is missing. In order 
to compensate this loss Camelidae make use of various mechanisms such as a higher 
somatic diversification rate (Conrath et al., 2003). 
The diversification of antibody molecules results from processes like somatic 
hypermutation which preferably takes place at so called hypermutation hotspots such as 
AGY and TAY motif (Y = C or T) (Nguyen et al., 2000) improving the binding affinity of 
antibodies. The fact that VHHs have a higher rate of somatic hypermutation than VHs is due 
to the fact that Camelidae make use of a distinct set of V genes encoding the V domain of 
hcAbs (Nguyen et al., 2000). This tendency for a higher somatic hypermutation rate can be 
observed in the sequences of HIV-1 capsid protein specific VHHs for example. The clones HIV-
1_1p#1 and HIV-1_1p#4 have identical CDR3s, but they differ in their CDR1 by two out of 
nine amino acid residues (22%). The sequences of HIV-1_1p#3 and HIV-1_3p#4 have the 
same CDR3 and differ in the CDR1 by three out of nine (33%) and in the CDR2 even by 11 out 
of 16 amino acid residues (69%). In summary, the 41 analyzed VHHs against HIV-1 capsid 
protein comprise eight different CDR1s, seven different CDR2s and seven different CDR3s 
which are combined. 
Besides a higher somatic hypermutation rate due to the accumulation of new 
hypermutation hotspots (Nguyen et al., 2000), VHHs are diversified by VDJ recombination 
like conventional antibodies. This can be observed in the yH2AX library for example with 
yH2AX_primary#3 and #4 having identical CDR1 and CDR2 but differ in the CDR3 which is 
due to the use of different D segments during VDJ recombination with the CDR3 loop 
providing important contacts with the antigen (Muyldermans et al., 1994) (De Genst et al., 
2006).  
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4.4 CDR3, disulfide bonds and functionality 
In addition to somatic diversification to compensate the loss of the VH-VL interaction and 
the resulting smaller antigen binding surface also the average length of CDR3s in VHHs is 
longer than in VHs (Conrath et al., 2003). This extension not only results in a larger antigen-
binding area but also increases the structural diversity of VHHs (Conrath et al., 2003) 
enabling VHHs to bind structures not recognized by conventional antibodies such as active 
clefts of enzymes with inhibitory or modulating effects (Transue et al., 1998). Since VHs and 
VHHs use the same set of D and J segments, the emergence of the longer CDR3s may be 
explained by the use of longer D genes or the connection of two D genes (Muyldermans, 
2001). The extended CDR3 of VHHs is often stabilized by an additional disulfide bond. This 
additional disulfide bond is formed with a cysteine in the CDR1 or CDR2 (Muyldermans, 
2001). 
In general, disulfide bonds are not formed within the reducing environment of the 
cytoplasm making conventional antibodies useless for an application in living cells. The 
sequence of hDnmt1-mCh_2pC6 has an extended CDR3 and one additional cysteine residue 
in the CDR2 and the CDR3, respectively. However, the intracellular recognition of hDnmt1 by 
the VHH seems not to be impaired by the reducing environment of the cytoplasm resulting in 
the absence of disulfide bonds. This particular VHH detects its antigen as good as the other 
three hDnmt1 specific VHHs containing no additional cysteines in living cells. 
The extended CDR3 of VHHs is often associated with their ability to bind hidden epitopes 
like active sites of enzymes (Lauwereys et al., 1998; Conrath et al., 2001; Muyldermans, 
2013). The often described inhibitory effect of VHHs cannot be observed with the selected 
VHHs for hDnmt1. One explanation may be the missing formation of the disulfide bonds 
resulting in a different loop structure which does not fit in the active site. Nevertheless, the 
formation of the disulfide bond in VHHs does not seem to play an important role for the 
visualization of the antigen. 
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During this thesis VHHs specific for different domains of the HIV-1 capsid protein were 
generated. The HIV-1 capsid protein consists of two domains, the N-terminal and the C-
terminal domain. In the mature HIV-1 capsid a dimerization interface between the C-
terminal domains of two capsid proteins is described (Mateu, 2009). The VHH specific for 
HIV-1 N-terminal-domain (HIV-Nterm#1) comprises an extended CDR3 and two additional 
cysteines in the CDR3 and has been shown to specifically recognize the HIV-1 capsid protein 
in living cells allowing for the visualization of HIV-1 capsid protein without interference with 
its functionality (Helma et al., 2012). Contradictory to the extended CDR3 of HIV-Nterm#1, 
HIV-1 C-terminal domain specific VHHs comprise an extreme short CDR3 (Figure 56 D). From 
the crystal structure (see Figure 56 A) it gets clear that HIV#9 crucially involves framework 
residues for antigen binding and the CDR3 plays only a minor role. HIV#9 binds to the HIV-1 
capsid region which is important for the dimerization of the capsid protein C-terminal 
domains. The differential involvement of CDR3s in antigen binding was also shown with two 
VHHs specific for GFP (Kirchhofer et al., 2010). The GFP-minimizer (Figure 56 B) comprises an 
extended CDR3 which is used to target GFP. In contrast, the GFP-enhancer (Figure 56 C) 
which has a short CDR3 uses both CDR2 and CDR3 to bind its antigen. However, both VHHs 
influence the fluorescence properties of their antigen. 
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Figure 56: Examples of VHH:antigen complexes. (A) HIV#9 with HIV-1 capsid C-terminal domain (PDB accession code: 2xt1). HIV#9 = cyan, HIV-1 capsid C-terminal 
domain = grey. (B) GFP-minimizer with GFP (PDB accession code 3g9a). GFP-minimizer = colored in cyan, GFP = grey. (C) GFP-enhancer with GFP (PDB accession code: 3k1k). 
GFP-enhancer = cyan, GFP = grey. (D) Amino acid sequence alignment of HIV#9, GFP-minimizer and GFP-enhancer. In all four figures, CDR1s are colored violet, CDR2s are 
colored blue and CDR3s are colored green. 
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4.5 Outlook 
VHHs have an significant potential for various applications in basic research, diagnostics 
and therapy. Their small size and structure enables the recognition of epitopes not 
detectable by conventional antibodies or antibody fragments. In addition, VHHs have the 
unique feature of functionality inside living cells. However, the generation of antigen specific 
VHHs is challenging since many factors such as immunogenicity of the antigen, selection 
method and intended downstream application influence the generation process. The 
development of the native panning method presenting antigen which is properly folded in 
combination with the F2H assay enables to identify VHHs recognizing native conformations. 
The generation of VHHs recognizing peptides, non-protein components or 
posttranslational modifications is especially demanding since VHHs prefer to bind 3-
dimensional epitopes. However, in particular the potential of recognizing posttranslational 
modifications is one of the most promising applications of VHHs since today these structures 
can only be made visible by conventional antibodies in fixed cells. A live cell application for 
the detection of such structures would enable scientists to get a more detailed and 
authentic insight into these dynamic processes. In order to find VHHs specific for such 
structures, the use of naïve libraries in combination with high-throughput panning and 
subsequent mutagenesis may be advantageous. VHHs selected from naïve libraries are not as 
affine as VHHs selected from an immune library. However, this attribute may be 
advantageous for live cell applications where strong binding of the VHH to its antigen may 
unintentionally influence the behavior of the antigen.  
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5.2  Abbreviations 
µM: micromolar 
µm: micrometer 
aa: amino acid 
BSA: bovine serum albumin 
CDR: complementarity determining region 
DAPI: 4´, 6-diamidino-2-phenylindole 
DNA: desoxyribonucleic acid 
Dnmt1: DNA methyltransferase 1 
EDTA: ethylen-diamine-tetra-acetate 
e.g.: for example 
ELISA: enzyme-linked immunosorbent assay 
EtBr: ethidiumbromide 
F2H: fluorescent two-hybrid 
Fab: fragment antigen binding 
GFP: green fluorescent protein 
GST: glutathione S-transferase 
HEK: human embryonic kidney cell line 
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HRP: horseradish peroxidase 
i.e.: id est (that is) 
Ig: immunoglobulin 
IgA: immunoglobulin A 
IgE: immunoglobulin E  
IgG: immunoglobulin G 
IgM: immunoglobulin M 
IL: interleukin 
IP: immunoprecipitation 
kDa: kilodalton 
LacI: lac repressor 
OD: optical density 
PCNA: proliferating cell nuclear antigen 
PCR: polymerase chain reaction 
RFP: red fluorescent protein 
RNA: ribonucleic acid 
Rpm: rounds per minute 
RT: room temperature 
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S: second 
scFv: single chain variable fragment 
SDS-PAGE: sodium dodecylsulfate polyacrylamid gel electrophoresis 
TCR: Tcell receptor 
VH: heavy chain variable domain of a conventional antibody 
VHH: heavy chain variable domain of a heavy chain antibody 
VL: light chain variable domain of a conventional antibody 
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